WO1993006921A1 - Particles, method of preparing said particles and uses thereof - Google Patents

Particles, method of preparing said particles and uses thereof Download PDF

Info

Publication number
WO1993006921A1
WO1993006921A1 PCT/SE1992/000692 SE9200692W WO9306921A1 WO 1993006921 A1 WO1993006921 A1 WO 1993006921A1 SE 9200692 W SE9200692 W SE 9200692W WO 9306921 A1 WO9306921 A1 WO 9306921A1
Authority
WO
WIPO (PCT)
Prior art keywords
phase
particles
cubic
liquid crystalline
homogeneous
Prior art date
Application number
PCT/SE1992/000692
Other languages
French (fr)
Inventor
Tomas Landh
Kåre LARSSONS
Original Assignee
Gs Biochem Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US77101491A priority Critical
Priority to US771,014 priority
Application filed by Gs Biochem Ab filed Critical Gs Biochem Ab
Priority to PCT/SE1992/000692 priority patent/WO1993006921A1/en
Priority claimed from DE1992629640 external-priority patent/DE69229640D1/en
Publication of WO1993006921A1 publication Critical patent/WO1993006921A1/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02Making microcapsules or microballoons

Abstract

Particles, especially colloidal particles, comprising an interior phase of a non-lamellar reversed cubic, intermediate or hexagonal liquid crystalline phase, or a homogeneous L3 phase, and a surface phase of a lamellar crystalline or liquid crystalline phase, or an L3 phase. A method of preparing such particles by creating a local dispersible phase, within the homogeneous phase, preferably by means of a fragmentation agent, and fragmentating the homogeneous phase so as to form said surface phase. Several medical as well as non-medical uses of the particles referred to, e.g. as an antigen-presenting system, as a delivery system for anticancer, antifungal and antimicrobial drugs, and as carriers of nucleic acids or nucleotides.

Description

TITLE

PARTICLES, METHOD OF PREPARING SAID PARTICLES AND USES THEREOF

1. Field of the invention

The present invention relates to the field of amphiphilic-solvent based systems and more specifically the fragmentation of such systems by means of a novel method. Thus, by means of said novel method systems, whi are otherwise homogeneous and in equilibrum, can be fragmented into small particles, especially colloidal particles. These new particles are extremely well suited as e.g. drug delivery particles or systems, but are also useful for several other medical as well as non-medical applications. Thus, the invention also encompasses said new particles as well as valuable uses thereof.

2. Background of the invention The use of reversed cubic and liquid crystalline phases in the field of controlled release devices is described in EPO 125 751 (Engstrόm et al 1983). However, there are many applications where the use of a homogeneo phase is not manageable. By the present invention it has become possible to prepare particles, especially colloid particles, of such phases or similar phases, viz by means of a new fragmentation technique. The importance of said new technique, and the new particles obtained thereby, ca be better understood from the following brief review of the prior art concerning other types of particles and homogeneous phases.

2.1. Dispersed lipid-based systems in pharmaceutical preparations Essentially, there have to date been three major par ticulate colloidal lipid-water systems which have been considered as suitable for drug delivery, namely such based on the lamellar mesophase as liposomes, micellar- -based phases including micelles, reversed micelles, and mixed micelles and various kinds of emulsions including microemulsions, as well as more novel carriers as ISCOM's (Morein 1988) (a general text concerning these systems is Pharmaceutical dosage forms, Disperse systems 1988). The latter system has been utilized for intravenous nutrition since the beginning of this century and as an adjuvant system known as the Freunds adjuvant. These are of oil-in -water (O/W) and water-in-oil ( /0) types, respectively. Liposomes have since their discovery been extensively investigated as drug delivery systems for various routes and drugs. The development of new colloidal drug carrier systems is a research area of intensive activity and it i likely that new systems, especially new emulsion based systems, will appear in the near future (cf. einer 1990a, 1990b). Lipid-based vehicles can take several different morphological forms such as normal and reversed micelles, microemulsions, liposomes including variants as unilamel- lar, multilamellar, etc., emulsions including various ty¬ pes as oil-in-water, water-in-oil, multiple emulsions, etc., suspensions, and solid crystalline. In addition so called niosomes formed from nonionic surfactants have been investigated as a drug vehicle. The use of these vehicles in the field of drug delivery and biotechnology is well documented (Mulley 1974, Davis et al. 1983, Gregoriadis 1988a, Lieber ann et al 1989). Particularly in the field of drug delivery the use of lipid-based drug delivery sys¬ tems, especially dispersed systems, has attained increas- ing interest as the pharmaceutical industry is developing more potent and specific - and thus more (cyto)toxic - drugs. This is because the vehicle can in principle reduce such toxic effects and/or side-effects, due to sustained release or increased site-specificity. The current inven- tion is easily distinguished from these earlier lipid- -water based systems, as follows: The term liposomes is conceptually wrong in view of the current knowledge of polymorphism of lipids. Liposome means "lipid body" and has by many authorities in the field been defined as any structure with an enclosed vo- lume that is composed of lipid bilayers (see eg. Tice and Tabibi 1992). This is not only very misleading but also conceptually wrong. Such a definition means that any dis¬ persed lipid based structure built up by a bilayer should fall into this category of device without regarding the different crystallographic aspect of the undispersed, homogeneous, phase from which the particulate vehicle is derived. It would, however, not include dispersions in which the interior of the particles is made up by reverse hexagonal phases, since they are built up by a monolayer, rather than a bilayer. Unfortunately, the concepts of lipid polymorphism and in particular the more complex structures of cubic liquid crystalline phases are often overlooked. Since the current disclosure is in the field of lipid-based vehicles, in which various reversed lyotro pic liquid crystalline phases are enclosed in a volume whose boundary is made up by L3 phase or lamellar crystal line phase or lamellar liquid crystalline phase, or a com bination thereof, it should be stressed that the current invention encloses either lipid bilayer or monolayer structures different from the lamellar phase. The ordered interior of each particle in the current invention is a portion of a lipid-water microstructured phase that is a thermodynamically stable phase, either a cubic, hexagonal intermediate phase or an L3 phase. The L3 phase is not classified as a liquid crystalline phase, as the others, rather it is an isotropic solution phase, using the stan¬ dard nomenclature in the literature of amphiphile micro- structures. The physical properties of the homogeneous re versed liquid crystalline phases used in the currect dis- closure are those presented in the patent by Engstrom et al. (1983) referred to. In the cases where a cubic phase constitutes the interior of the particles it is built up by a bi- or multicontinuous interpenetrating network mic rostructure, at the scale of nanometers. This makes thes phases unique with regard to compartmentalization since the two independent interpenetrating networks separated the bilayer can be distinguished, and endows them with e tremely high specific surface area, which is especially important in the formulation of amphiphilic drugs that straddle hydrophobic and hydrophilic microdomains.

The current invention is thus easily and sharply dis tinguished from both liposomes, emulsions, microemulsions as well as various microencapsulated emulsions, hydrogels and reversed micelles. Most obviously, the enterior phase(s) of the current particles is (are) a thermodynami equilibrium phase, and thus appears as a discrete region in a phase diagram which obeys the phase rule of Gibb's and other laws of chemical and thermodynamical equilibria this is in sharp contrast with liposomes and emulsions, which are non-equilibrium states or morphologies. [Note that we are using the convention of referring to equilib- rium structures as "phases" and non-equilibrium structure as "states"]. In the case of emulsions the interior is also thermodynamical stable, but it is an interior which lacks long-range order, and is not composed of either li¬ pid bilayers or lipid monolayers, or analogous structural elements. This is a clear distinction, which is directly accessible to experiment, since the interior phase used i the current particles give rise to Bragg peaks on examina tion with small-angle X-ray (or neutron) scattering tech¬ niques, in accordance with its lattice ordering; thus the Bragg peaks recorded can be indexed to e.g. a simple cubic, body-centered cubic, or face-centered cubic lat¬ tice, hexagonal lattice, or tetragonal lattice in the cas the interior is made up by a cubic phase, a hexagonal phase or intermediate tetragonal phase, respectively. In contrast, no case has ever been reported in which multiple Bragg peaks, indexing to any of these lattices, were re¬ corded in a small-angle scattering experiment on a liposo- mal dispersion or an emulsion. Clearly, the surface of t current particles can in practice give rise to diffractio indexing on a lamellar lattice. In the case of microemul¬ sions and reversed micellar phase, both lacking long rang order, they are clearly distinguished from the L3 phases in the current surfactant literature.

The distinctions between the current invention on th one hand, and the liposomal dispersions and emulsions on the other, then follow directly from the above distinc- tions, and it is only in the case of the reversed liquid crystalline phase dispersions disclosed herein the inte¬ riors of the particles are substantially composed of regions of reversed liquid crystalline phase(s).

In the case of dispersions of L3 phases, the inte- riors of the particles are not composed of liquid crystal line material but of the to the cubic phases closely re¬ lated L3 phases. The L3 phases are thermodynamic equili¬ brium phases, distinguishing them from liposomes and emul sions as in the case of cubic phases. The lipid film form a highly connected bilayer as in the cubic phase, again i contrast with the liposomes and emulsions. However, in this case scattering experiments do not reveal long-range order as in the cubic phase.

Of special importance in formulations, used either for drug delivery or for biological or biotechnological applications, is the position and orientation of the compound with respect to the bilayer. In the current in¬ vention specific orientation may be readily achieved in the case the interior is composed of cubic phase, for which it is an inherent property, as opposed to liposomal bilyaers. This substantially simplifies the process of standardizing enzyme activity in the formulation. Such selectivity in membrane topography is not easily estab¬ lished in other lipid-based systems such as liposomes and emulsions. There are several other areas of interest wher the presented topography of the compound is of profound importance, as with antigen presentation in immunization processes. The current invention can accomplish the optimization of this presentation for both extracellular and intracellular targets.

2.2. Homogeneous liquid crystalline phases in pharmaceu¬ tical preparations

Liquid crystals do participate in the microstructure of pharmaceutical preparations, and probably do so more frequently than is usually expected. The use of homoge- neous reversed cubic and hexagonal phases as a controlled release system for use in e.g. drug delivery systems was invented by Engstrom, Larsson, and Lindman in Lund, Sweden, who are holders of a current patent (Engstrom et al. 1983, see also Ericsson et al 1991, and references therein). Dr. D. Attwood and coworkers in Manchester, UK, have also investigated the use of cubic phases for the purpose of drug delivery (cf. Burrows et al 1990).

Cf. also Mueller-Goymann and collaborators (Mueller- -Goymann 1985, Mueller-Goymann 1987, Mueller-Goymann 1989 and references'within these works). Other contributions occur in the literature (cf. Ibrahim 1989, Tyle 1990) and are not restricted to lyotropic liquid crystals (Loth and Euschen 1990).

2.3. Dispersed reversed cubic liquid crystalline phases There have been speculations of the existance of dispersed cubic liquid crystalline phases in connection with fat digestion (cf. Lindstrδm et al 1981) and recently Larsson (1989) suggested a structure of such cubic phase dispersions; in these, the surface layer was proposed to be a lamellar phase, which immediately distinguishes such dispersions from the particles whose surface phase is L3 phase disclosed herein - the particles in this embodiment of the present invention are isotropic throughout, whereas those discussed by Larsson (1989) contain anisotropic, birefringent regions which are easily detected in the polarizing microscope. The only exception is particles. described in the present disclosure, which are surrounded by a lipid structure which is crystalline, not liquid crystalline as in the lamellar phase. Regarding the case of dispersions of reversed liquid crystalline phases by the use of a lamellar liquid crystalline phase as a dis- persable phase the novel fragmentation technique accordin to the invention can be used.

2.4. Phase behavior in lipid-water based systems and the determination of cubic phases

A "lipid" is, in a broad view, defined as any mole¬ cule containing a substantial part of hydrocarbon. How¬ ever, only those lipids that contain a hydrophilic polar part can give rise to liquid crystals by interactions wit water. The basis for lipid lyotropic (and thermotropic) mesomorphism, and the formation of lipid assemblies, is the duality in solubility resulting from the presence of apolar (hydrophobic) and polar (generally hydrophilic) regions of the surfactant molecule - that is, its amphi- philicity (or amphipaticity) . Amphiphilic lipids can be classified according to their interactions with water int nonpolar and polar (Small 1986). Where applicable within this disclosure we are concerned with lipids or lipid-lik amphiphiles that exhibit mesomorphism and are thus classi fied as polar, insoluble and swelling amphiphiles. If nothing else is said we use the terminology introduced by Luzzati and associates (see Mariani et al. 1988, and ref. therein) .

The principal techniques for studying the different phase structures are polarizing microscopy, X-ray diffrac tion, nuclear magnetic resonance (NMR) spectroscopy and electron microscopy techniques. Other techniques, as dif¬ ferential scanning calorimetry (DSC) and rheology can be used to give complementary information. Unambiguously phase determinations of the phases constituting the inte¬ rior as well as the exterior is a prerequisite in order t classify dispersions according to the current invention. Preliminary phase behavior is usually carried out by tex¬ ture analysis between crossed polarizers and more detaile in a polarizing microscope (Rosevear 1968). X-ray diffrac tion techniques are the obvious methods to deduce the sym metry of liquid crystals. The characterization of lipid mesophases by diffraction (Luzzati 1968) is based firstly on symmetry and the interpretation is normally based on treating the diffraction photographs as powder patterns. The long-range order of the assemblies in either one, two, or three dimensions, give rise to reflections which are converted to interplanar spacings. It is only with X-ray diffraction studies phase assignments can be regarded as unambiguous.

2.4.1. Phase diagrams in lipid-water systems

Fontell (1990) gives a comprehensive and systematic reveiw on cubic phase forming lipids and lipid-like sur¬ factants and the occurrence of the cubic phases in the phase diagram and their relation to other phases. The in- formation obtained from the structure of the neighboring phases can often be valuable for the identification of a cubic phase. The fact that a mesophase, such as the cubic or hexagonal phase, is in equilibrium with excess of water, is itself a strong indication that the structure is of the reversed, type II topology.

In the context of this invention, two examples of lipid-water based systems have been investigated with the objective of mapping the underlying phase behavior so as to understand and develop the techniques disclosed herein regarding the fragmentation process: Commercially availab¬ le products have been used throughout this study, and it is important to note that these are generally not single- -component products. We first discuss the binary phase diagram of the glycerol monooleate (GMO)-water system. The GMO has been obtained through molecular distillation of pine-needle oil (Grinsted, Denmark), and has a monogly- ceride content of > 98%, of which 92.3% is monoolein (MO) (MO refers to the pure monoolein, while GMO refers to a monoolein rich monoglyceride blend). Many phase diagrams have been reported involving cubic phases of monoglyce- rides (Lutton (1965), Larsson et al. 1978, Krog and Larsson 1983, Larsson 1989, Krog 1990). In addition to th pure lipids monoolein, monoelaidin, monolinolein, mono- arachidin, and monolinolein (Lutton 1965, Larsson et al. 1978, Hyde et al. 1984, Caffrey 1989), several blend qualities of monoacylglycerides are well characterized an known to form cubic phases in equilibrium with water

(Larsson and Krog 1983, Krog 1990). Significantly, these blends are available at low production costs, typically less than $2 per pound.

Monoacylglycerides are often used in cosmetic pro- ducts (Cosmetic Ingredient Review expert panel 1986), foo industry (Krogh 1990) and pharmaceutics (Martindale the extra pharmacopoeia 1982), and are generally recognized a safe (GRAS) substances and as indirect food additives or human consumption without restrictions as to their concen- trations. Federal regulations allow the use of monoglyce- rides, blends thereof, and blends of mono- and diglyce- rides as prior-sanctioned food ingredients and as both indirect and direct food additives. Furthermore, the meta¬ bolic fate of monoglycerides (and glycerides in general) is well documented in the human body. In the cosmetic industry monoglycerides and blends thereof, especially monoolein, are used as emulsifiers and thickening agents and recognized as safe cosmetic ingredients at concentra¬ tions up to 5% (Cosmetic Ingredient Review expert panel 1986).

The fact that there exists cubic phases in equilib¬ rium with excess of water in the above mentioned monogly¬ ceride systems is a strong indication that the cubic phase is of the reversed, type II topology. This has been veri- fied by self-diffusion NMR (Lindblom et al. 1979). It should be pointed out that several systems which form cubic phases of the reversed type exhibit cubic mesomor- phism, i.e. the appearance of a sequence of distinguish¬ able cubic phases with different physical appearance, as well as exhibiting different lattice characteristics. Th phase behavior of the present GMO-water system was found to be very similar to that of MO-water reported by Hyde e al. (1984) (Engstrom and Engstrom 1992). The Q 224 was found to be the cubic phase which coexists with excess of water.

The second lipid-water system used is the ternary system of GMO-soybean lecithin (SPC)-water. SPC is a pure phosphatidylcholine with the trade name Epikuron 200 whic is well-characterized (Bergenstahl and Fontell 1983). It shares the general features of the phase diagram for M0- dioleoyl phosphatidylcholine-heavy water system reported by Gutman et al (1984). The existence of three cubic phases within the cubic region is experimentally verified by X-ray diffraction, as was the coexistence of cubic phases with excess of water.

2.4.2. Phase behavior and phase diagrams in lipid-protein -water systems

The phase properties in lipid-protein-water mix¬ tures is a relatively unexplored area of research. Most o the studies have been reported by the groups of Gulik- Krzywicki, Luzzati and colleagues (cf. Mariani et al.

1988, Gulik-Krzywicki 1975), by De Kruijff and coworkers (cf. Killian and De Kruijff 1986) and by Larsson and co- workers (cf. Ericsson et al. 1983, Ericsson 1986). Most studies address the behavior in diluted systems and often deal with the stability of the lamellar phase vs. the reversed hexagonal phase. The induction of non-lamellar phases is well established for quite many systems. Some works address the phase properties vs. the activity of membrane bound enzymes, and it has been possible in some works to establish a correlation between an increased enzyme activity and isotropic movement of the lipid matrix. In the field of enzyme catalysis in microemul- sions, some studies deal with the phase behavior; however few works present phase diagrams.

That the cubic phases in the monoolein (MO)-water system could host quite large amounts of various substan- ces, included proteins, had been known for many years (cf Lindblo et al. 1979). The phase diagram of MO-lysozyme- -water displays the general features of MO-protein-water systems, in cases where the protein is located in the aqueous labyrinths of the cubic phase (Ericsson et al. 1983). Ericsson (1986) reported a considerable number of proteins which can be incorporated within the MO-water cubic phase.

The second system which has been investigated in considerable detail is the MO-cytochrome c-water system reported by Luzzati and coworkers (Mariani et al. 1988), and it exhibits the general features found in the MO-lyso zyme-water system. However, it also shows some features which necessary must arise from the protein; noteworthy i the existence of a chiral, non-centrosymmetric cubic phase, with space group 212. These aqueous MO-protein systems all exhibit at least one cubic phase which fulfil the criteria for constituting the interior phase of the particles according to the present invention.

2.5 Structure of the interior phases

The interior of the particles according to the inven¬ tion consists of reversed lyotropic liquid crystalline phases, chosen from the group of reversed cubic liquid crystalline phases, reversed intermediate liquid crystal- line phase, and reversed hexagonal liquid crystalline phase, or L3 phase, or a combination thereof. These phases are all well characterized and well established in the field of polymorphism of lipids and surfactants. 2.5.1. Structure of the cubic and hexagonal phases

Several reviews are available where cubic phases are discussed; see e.g. Luzzati (1968), Fontell (1974, 1978, 1981), Ekwall (1975), Tiddy (1980) and Luzzati et al. (1986). In recent years several surveys devoted to cubic phases have appeared. Luzzati and associates (Mariani et al. 1988) (see also Luzzati et al. 1987) give a detailed crystallographic description of the current situation with regard to the structure of the six cubic phases observed so far. Lindblom and Rilfors (1988) have reviewed the occurrence and biological implications of cubic phases formed by membrane lipids, and Larsson (1989) has reviewed the latest developments in the study of cubi lipid-water phases. A comprehensive review of the occur- rence of cubic phases in literature phase diagrams was recently presented by Fontell (1990).

A general classification of the cubic phases is still not available. However, in the case of bilayer-biconti- nuous cubic phases in binary systems they can be classi- fied according to their interfacial mean curvature as

"normal" (type I) or reversed (type II) cubic phases. Type I cubic phases are those whose mean curvature at the apolar/polar interface is toward the apolar regions. Contrarily, type II or reversed cubic phases are those whose interface is towards the polar regions. In connec¬ tion with the invention we are only concerned with cubic phases of type II, i.e. reversed.

Regarding the structure of the hexagonal phase it consists of hexagonally arranged rods of water (solvent) surrounded by a monolayer of amphiphile (see e.g. Seddon 1990, for a review).

2.5.2. Structure of the L3 phase

The microstructures of the L3 phases referred to are similar to those frequently found in surfactant-water systems (Benton et al. 1983, Porte et al. 1988, Gazeau et al. 1989, Anderson et al. 1989, Strey et al. 1990a, Strey et al. 1990b, Milner et al. 1990). The acquiescent L3 phase is isotropic. However, one striking and characteris tic feature is that it shows extended flow birefringence. Other characteristics include long equilibration times and, at least relative to the amphiphile concentration, high viscosity. The structure is generally believed to be built up of multiply-connected bilayer forming a bicon- tinuous structure of high connectivity, and it may be regarded as a disordered counterpart to the cubic phases (Anderson et al. 1989), possessing similar topological connectivity and a local bilayer structure, but lacking long-range order.

2.6. Structure of the surface or dispersable phases The structure of the L3 phase when used as the dis¬ persable or fragmenting phase is exactly as described in 2.5.2. It should be pointed out that one bilayer of an L3 phase can not readily be distinguished from a lamella of a diluted lamellar phase. Similarly, it has been pointed out that the L3 phase may in certain systems exhibit metasta- bility (Dubois and Zemb 1991) in which a transformation of the L3 phase to a lamellar phase was observed after 3 weeks of equilibration time. The lamellar structures, in¬ cluding lamellar phases with: disordered chains, untilted ordered or gel, and tilted gel, used as the dispersable phases are described by Luzzati (1968).

3. Disclosure of the invention

The present invention relates to new particles, espe- cially colloidal particles, made from reversed cubic, he¬ xagonal or intermediate phases, or L3 phases, or mixtures thereof, by fragmentation of the corresponding homogeneous structure. Fragmentation can be achieved through several processes described below. The resulting particles are thus composed of an interior amphiphilic-based phase sur¬ rounded by a surface phase anchored to the bi- or mono- layer of the interior phase. The properties of the surface phase is such that it can easily be dispersed.

Thus, the present invention is in the field of lipid -based dispersed vehicles representing novel drug deliver systems. The invention is nonetheless sharply distinguish ed from liposomes and emulsions, and similar particulate vehicles as well as from the techniques used for the pre¬ paration of such lipid-based particulate systems. The class of delivery vehicles claimed comprises particles whose interiors are substantially composed of lyotropic liquid crystalline phases of bilayer or monolayer type, o the closely related L3 phases which lack long-range super molecular order; the reversed lyotropic liquid crystallin phases can be chosen from the group consisting of the cubic phase, the hexagonal phase, and the intermediate phase, or a combination thereof, using the nomenclature i the current surfactant literature. These liquid crystals are thermodynamic equilibrium phases, in contrast with li posomes and emulsions which are metastable. With the in¬ terior of the current particles being liquid crystals, they exhibit Bragg peaks in small-angle X-ray scattering (SAXS) experiments, as opposed to liposomes and emulsions which do not possess long-range crystallographic order on the microstructural length scale, namely lattice parame¬ ters in the range of nanometers or more. Dispersions of the liquid crystals loaded with an active compound can be conveniently prepared by fragmentation of the homogeneous liquid crystal. A variety of techniquies disclosed herein can be used for the fragmentation process, creating dif¬ ferent surface properties of the particles, depending on the choice of dispersable phase and its composition. The fragmentation can be spontaneous or aided by standard homogenizing means such as valve homogenizers. The disper¬ sions can display long-term stability.

More specifically the new particles according to the invention comprise an interior phase of a non-lamellar lyotropic liquid crystalline phase selected from the group consisting of a reversed cubic liquid crystalline phase, a reversed intermediate liquid crystalline phase and a reversed hexagonal liquid crystalline phase, or a homogeneous L3 phase, or any combination thereof, and a surface phase selected from the group consisting of a lamellar crystalline phase and a lamellar liquid crystal¬ line phase, or an L3 phase, or any combination thereof. Thus, the invention makes use of non-lamellar, but equilibrium, reversed lyotropic liquid crystalline phases that occur in many lipid-water and other amphiphile-sol- vent based systems. The following terminology is used: The particles whose inner is made up by non-lammelar phases, the interior phase, are prepared by a novel fragmentation procedure which makes use of the introduction of discli- nations/defects in the interior phase by the local forma- tion of a dispersable phase such as the L3 phase, lamellar liquid crystalline phase, or lamellar crystalline phase, or a combination thereof. The so formed disclinations, whose boundaries make up the dispersable phase referred to as the surface phase of the particles, in turn constitute the boundary of a fragment of the interior phase of the particles. The fragmentation procedure takes place in such a way that it guarantees the coexistence of the phase making up the interior, the phase making up the surface, and the solvent-rich solution phase. The latter is most often rich in water, or any other polar solvent, or sol¬ vent in which the interior phase(s) of the particles is(are) formed. A three phase region can hence be deter¬ mined as the region of which these phases coexist and in which the interior phase is fragmented according to above. The particle size can thus be varied to a certain extent since the amount of dispersable phase will determine the maximum sum of surface area of the particles. The inven¬ tion makes use of phases constituting the interior phase chosen from the group of reversed cubic liquid crystalline phases, reversed hexagonal liquid crystalline phase, and reversed intermediate liquid crystalline phase, or a combination thereof, or an L3 phase. It is in fact a prerequisite that when the interior phase is a liquid crystalline phase it is of reversed type since it must be able to coexist with the solvent-rich phase.

More specifically the method according to the invention comprises forming a homogeneous, non-lamellar lyotropic liquid crystalline phase selected from the grou consisting of a reversed cubic liquid crystalline phase, reversed intermediate liquid crystalline phase and a reversed hexagonal liquid crystalline phase, or a homogeneous L3 phase, or any combination thereof, creatin a local dispersible phase, within said homogeneous phase, of a phase selected from the group consisting of a lamel¬ lar crystalline phase and a lamellar liquid crystalline phase, or an L3 phase, or any combination thereof, in the presence of a solvent phase, said solvent being of a nature with which said homogeneous phase can coexist and wherein said dispersible phase can be dispersed, and fragmentating said homogeneous phase so as to form particles, the interior phase of which comprises said homogeneous phase and the surface phase of which comprises said dispersible phase.

Generally, a fragmentation agent is used to establish the final appearance of the interior phase as well as the surface phase, even though it may only be a change in lattice parameter of the interior phase, or the establish¬ ment of a new interior phase not present in the system lacking the fragmentation agent.

The structure of the surface phase can vary depending on the preparation of the particles to be either diluted lamellae (lamellar liquid crystalline phase), lamellar crystalline phase, or an L3 phase. The colloidal frag¬ mented L3 phase particles are made from cubic phases through lyotropic phase transformation of the dispersed cubic phase. Alternative formulations resulting in sub- stantially the same final microstructure for the disper¬ sion fall within the scope of this invention. Especially preferable embodiments of the particles a well as the method according to the invention show those characteristic features which are claimed in the accompanying claims. These embodiments as well as other embodiments of the invention will now be described more i detail.

3.1. Dispersions of reversed liquid crystalline phases A convenient starting point for the formation of cubic phase dispersions is a cubic phase that can be in thermodynamic equilibrium with excess of water or aqueous (molecular or dilute micellar-like) solution. We describe only the invention exemplified in detail with the case of cubic phase interior, since exactly the same procedure ca be applied to sytems possessing a reversed hexagonal or intermediate phase in excess of water. Several systems in which a cubic phase coexists with a very diluted aqueous solution have been described in the literature (for a re¬ view, see Fontell 1990), all of which can in principle be applied to the current invention. Many monoacylglyceride- -water systems possess this feature (see 2.4.) and are suitable to exemplify the invention.

MO may be considered as a fusogenic lipid and can generally not be regarded as blood compatible, at least not as a monomer or as assembled in the cubic phase. How¬ ever, the particles claimed are blood compatible (with the exception of the dispersion with a crystalline outer pali¬ sade, discussed below) as indicated by the lack of lysis products after incubation with red blood cells for 1 hr. This may be attributed to the very hydrophilic palisade layer constituted by the surface phase, surrounding the particles. The surface phase can conveniently be chosen to be composed of polyethylenoxide units or glyco- moieties, or a mixture of these. In these cases, the palisade to some extent mimics the glycocalyx of blood cells. The chemical constituents of the cubic phase can further be varied by exchanging the monoglycerides by phospholipids such as soybean lecithin, egg yolk lecithin, pure phos¬ pholipids as dioleoylphosphatidylcholine, and diglyce- rides. By such means, the molecular constituents of the bilayer structure can be systematically varied so as to 5 achieve the desired properties as described in detail below.

Solubilized (active) component(s) also play a role the final properties of the formulation, especially if large amounts of active substance are incorporated. To 10. date, every compound which has been solubilized in the aqueous networks of a reversed cubic phase has been found to increase in solubility in comparison with that in aqueous solution. This has been found to be particularly pronounced in cases where the amphiphilic character of th 5 compound calls for the unique, amphiphilic compartmenta- lization afforded by the cubic phase, so that both solubi lity and stability are increased in the cubic phase. Such compounds are e.-g. global proteins and glycoproteins, polynucleotides and highly reactive lipids as prosta- 0 glandins and their derivatives as thromboxanes. We strong ly emphasize that the current invention is applicable to any reversed liquid crystalline phase defined as the interior, and to any of the defined surface phases, and their coexistence in any type of solvent-rich media 5 (solution phase) regardless of their molecular composi¬ tion. The formulation of different molecules in the reversed liquid crystalline cubic and hexagonal phases is described by Engstrom et al. (1983).

Reversed cubic liquid crystalline phases can general 0 ly be fragmented by one of the following procedures a) - d): a) Add, to the equilibrated homogeneous cubic or inter¬ mediate phase, an aqueous solution, not necessarily any molecular solution, of one or more amphiphilic block co- 5 polymers where the hydrophilic lipophilic balance (HLB) of the block copolymer is higher than 15. Subsequent stirring with the appropriate equipment results in a coarse disper- sion of fragmented cubic phase which can be aftertreated as described below. Fragmentation agents belonging to thi group are certain poloxamers, such as poloxamer 407 and poloxamer 188 (Lundsted and Schmolka 1976a, Lundsted and Schmolka 1976b, Schmolka 1969) and certain amphiphilic proteins, such as casein.

Examples of other surface active polymers that can potentially be used as fragmentation or stabilization agents, either alone or in mixtures with the above, are glycoproteins as mucins and polysaccharides as alginate, propylene glycol alginate, gum arable, xanthan, carra- genan, polyvinylpyrrolidone (PVP) and carboxymethyl- cellulose. b) Add, to the equilibrated homogeneous reversed liquid crystalline phase, an aqueous dispersion of a mixture of one or more amphiphilic block copolymers, such as in pro¬ cedure b), and lipids, such as phospholipids, preferably such mixtures of phospholipids. The ratio of lipid to polymer should not be greater than required to maintain o establish the liquid crystalline phase constituting the interior according to above. c) Fragment the homogeneous cubic phase by means of ultra sonic devices under controlled conditions in a solution o amphiphilic substance(s), again generally of HLB 15 or more. Procedure c) can also be used in conjunction with procedures a) and b) to shorten processing times. d) Co-equilibrate the starting material, at elevated tem¬ perature, with an amphiphilic substance that forms a cubi or intermediate phase at the equilibration temperature an one. of the following structures at the temperature desire for the formulation (typically 37°C, physiologic tempera¬ ture): 1) a lamellar structure; 2) a lamellar crystalline structure; 3) an L3 phase. The fragmentation procedure is brought about through rapid cooling of the system in whic one of the structures 1-3 is formed at well-defined crys- tallographic planes in the cubic phase or at defects in the cubic phase. Examples of substances which can be potentially used for the introduction of particular surface phases include: class 1) phosphatidylcholines * such as phosphatidylethanolamine and ester derivatives thereof, phosphatidylinositol, phosphatidylglycerol, cationonic surfactants, such as didodeceyldimethyl ammo¬ nium bromide (DDAB), monoglycerides, all of which form lamellar phases in equilibrium with the interior phase a with excess of solution; class 2) monoglycerides forming lamellar crystalline phase in equilibrium with the cubic and excess solution phase; class 3) In addition to those given in procedure a) above phosphatidylglycerols and phosphatidylethanolamine, both with chain lengths of 18 carbons or above and unsaturated, can be mentioned. Repeated freeze-thawing cycles can be used to control particle size distribution, and the dispersion obtained can be aftertreated as described below.

All except procedure d) take place above the main transition temperature of the lipid bilayer or lipid mono layer constituting the interior phase. Any variation of the procedures a)-d) which utilizes the nature of the exact potentials, i.e. uses another pathway so to achieve substantially the same result as disclosed herein, fall within the scope of the current invention.

3.1.1. Examples of procedures a) and b)

Materials: A GMO prepared by molecular distillatio was purchased from Grindsted Products A/S, glycerol mono¬ oleate (GMO) (85-06) (074832-FF 8-009), (Braband, Den¬ mark), and consisted of 98.8% monoglycerides, 1.0% glyce- rol, 1.0% diglycerides and 1.0% free fatty acids. The fatty acid composition was C16:0:0.5, C18:0:2.0, C18:l:92.3, C18:2:4.3, C18:3:trace, C20:4:0.5 wt %, as stated by the supplier. Purified poloxamer 407, also named Pluronic F-127, was obtained from BASF Corporation (Wyan- dotte, USA). Soybean phosphatidylcholine (SPC) was pur¬ chased from Lucas Meyr (Epikuron 200) with a fatty acid pattern according to Rydhag (1979) of: C8:0.8, C12:2:12.2, C16:l:0.4, C18:2.7, C18:l:10.7, C18:2:67.2 and C18:3:6.0. Double distilled water was used in all experiments.

In the ternary phase diagram of the GMO/poloxamer 407/water system the solubility of the fragmentation agent, in this case poloxamer 407, in the cubic phase originating from the binary GMO/water system is such that it introduces the formation of a new cubic phase which is in equilibrium with an L3 phase which exists between 78-9 wt % of water and an aqueous phase. These three phases form the boundary of the constituents of the invention in this particular system, by the three phase region where the interior phase, the surface phase, and the solvent- rich solution phase coexist. Thus only one particular cubic phase, a cubic phase Q 229 with a lattice parameter of 15 nm and a composition of 50/3.5/46.5 wt % of

GMO/poloxamer 407/water, respectively, is fragmented by means of the introduction of disclinations caused by the local formation of the dispersable phase, the L3 phase, whose composition is 6.5/4/89.5 wt % of GMO/poloxamer 407/water, respectively. Mixtures of the compounds whose composition is such as it falls within the boundaries of the three phase region are readily fragmented, even spontaneously with some fragmentation agents acting by this mechanism. Such mixtures thus fall within the scope of the current invention.

The following procedures have routinely been used to produce the particles of the invention: Typically an aqueous poloxamer 407 solution was added to a homogeneous cubic phase GMO/water (65/35 w/w%). The amount of poloxa- mer 407 solution can be varied within the three phase region described, i.e., in the approximative range of 0.8 3.5 wt.% of poloxamer 407. When necessary, the mixture wa stirred on a magnetic stirrer until the cubic phase had fragmented into particles with the desired properties, such as size and adhesiveness. Typically water was added to a powdered GMO in the ratio 65/35 w/w %. The mixture was then equilibrated at room temperature for some hours until a clear isotropic phase was obtained, after which aqueous poloxamer 407 solution was added according to co centrations given above.

Analogous behavior of the GMO/poloxamer 407/water system is obtained if the poloxamer is changed to poloxamer 188 (Pluronic F68) instead of 407. In the GMO/poloxamer 188/water system the three phase region in which the cubic phase constituting the interior of the current invention has the composition 53/4/43 wt % of GMO/poloxamer 188/water and the L3 phase constituting the dispersable, or surface phase has the composition 10/18/7 of GMO/poloxamer 188/water. The three phase region in which the particles of the current invention can be pro¬ duced is thus defined. The fragmentation procedure itself, in these and the other systems presented, requires very little input of energy, and fragments of the interior phase are sponta¬ neously formed by simply mixing the components. In all systems homogenizing devices, e.g., valve homogenizers ca be used as described below.

The addition of any kind of compound which does not cause any unfavorable phase change (unfavorable in the sense that none of the herein disclosed interior phases i formed) behaves analogously to the systems described, and it is only the extension and location of the three phase region which is changed, due to shifts in the phase boun¬ daries, of the phase regions constituting the interior phase as well as the surface phase. For example, the system of GMO/soybean lecithin (SPC)poloxamer 407/water is found to behave analogously to the GMO/poloxamer 407/water and GMO/poloxamer 188/water systems. The same analogy holds for a variety of other compounds as well, exampli- fied by somatostatin and insulin as described below.

In addition to the above systems the inventors found the formation of the current particles in: the GMO/DDAB/- water system, with less than 3 wt % of DDAB, in which particles with an interior phase of cubic phase and an

SUBSTITUTE SHEET exterior of L3 phase are formed; systems of dioleoylphos- phatidylethanolamine (DOPE) in combination with DDAB and or GMO, as well as diacylglycerides such as diolein.

3.1.2. Structure of the dispersion formed according to procedures a) and b): Evidence for an intraparticle cubic phase

The strategy in the structural evaluation of cubic phase dispersions prepared according to procedure a) has been to use a combination of the following: i) phase dia¬ gram studies; ii) detailed SAX diffraction studies to com¬ plement the phase diagram studies and to verify directly the existence of cubic phases; iii) visualization of the dispersed structure by detailed light microscopy and electron microscopy (EM) studies; iv) 31P-NMR to verify the existence of isotropic signals in the dispersions, in¬ dicative of cubic or L3 phases; v) light scattering studies for the measurement of particle size distribu¬ tions. All steps in the evaluation procedure have been performed on homogeneous phases and on non-homogenized and homogenized dispersions, with the exception of EM which was not applied in the case of homogeneous phase studies. The results are summarized below.

3.1.2.1. The GMO/poloxamer 407 and poloxamer 188 and GMO/SPC/poloxamer 407-water systems From X-ray studies of the fine structure of the cubic phase swelled with poloxamer the inventors have shown that it is built up of a bilayer similar to the cubic phases in the GMO-water system but in which the PPO- -units of the poloxamer 407 are located in the bilyaer close to the apolar/polar interface with the PEO-units in the aqueous labyrinths. From this it is concluded that the observed decrease in the bilayer curvature of the cubic phases appears to be an effect of the PPO-units rather than the PEO-units. It is further proposed that the forma¬ tion of the colloidal fragmented dispersions of the cubic

SUBSTITUTESHEET phase is an ultimate consequence of the proposed fine structure and its relation to the formation of an L3 phase. Thus, the inventors have shown that the formation of the L3 phase which is governed by, among other things, a melting of the lattice structure and a simultaneous approximately two-fold increase of the characteristic length scale along a cubic/L3 tieline. This leads to a weakening of the interbilayer forces and a subsequent los of long-range order. This is utilized in the current in- vention, in such a way that the formation of the L3 phase acts very similar to an explosive, in that it bursts the homgoneous cubic phase. The pathway for the explosive force is the formation of the L3 phase, which takes place along the most cost-effective energy-minimized path. A pairticle will, however, not separate from the homogeneous cubic phase until the whole of its boundary is covered with L3 phase. This can very dramatically and readily be visualized in the polarizing microscope, in which the fragmentation procedure can be seen to take place under the formation of small streaks of birefringence along the cracks of the homogeneous cubic phase in an otherwise totally isotropic picture. Sometimes, fragments are sticked to the homogeneous cubic phase which indicates that the surface is not fully covered with L3 phase. The phase diagram of the GMO/poloxamer 407/water system is dominated by an extended cubic phase region ranging from 18 wt.% to about 67 wt.% water and with a maximum content of 20 wt.% poloxamer 407. At higher con¬ centrations of the poloxamer 407 the cubic phase "melts" into an isotropic L2 phase. The system exhibits four other one phase regions, one of which appears in the diluted region, in between a diluted lamellar phase and the cubic phase, viz an L3 phase. Its structure has been shown by the inventors to be the same as for the L3 phases fre- quently found in surfactant-water system (see 2.5.2).

SUBSTITUTESHEET Four cubic one-phase regions were verified experimen¬ tally by the existence of the necessary two-phase samples with clearly separated, subsequently identified cubic phases, and the existence of the necessary multiple-phase samples formed with the adjacent phase regions. The type of the cubic phases may be assumed to be of type II based on their location in the phase diagram. By means of SAXS the cubic phase which participate in the three phase region where fragmentation takes place can be determined. The same principle phase behavior is found in the GMO/po¬ loxamer 188/water and in the GMO/SPC/poloxamer 407/water systems, and the existence of a three phase region where the interior phase (cubic) and the surface phase (L3) coexist with an excess of water. In addition we have studied the phase behavior of the GMO/poloxamer 188/water at increased temperature to check for the critical tempe¬ rature when this three phase region disappears. No such temperature was found and the three phase region existed at least up to 60°C which was the highest temperature stu- died. A general decrease of the extension of the cubic phase was noticed to take place at high water content (low curvatures) which correlates nicely with the believe in increased entropy in the hydrophobic part of the bilayer as the temperature is increased. The most important fea- ture for this text is the existence of the three-phase region where the L3 phase and the cubic phase are coexist¬ ing with the diluted solution and in which region the current particles may be prepared.

3.1.2.2. Phase behavior in polypeptide- and protein-water systems and their dispersions

The phase behavior of the GMO-somatostatin-water system is similar to that of the MO/lysozyme/water system. Somatostatin, like most polypeptide hormones, has a very low solubility in water and tends to associate into va¬ rious types of molecular aggregates. The solubility of monomeric somatostatin (molecular weight 1637.9) in

SUBSTITUTESHEET aqueous solution has been estimated to be 0.3 mg/ml. Furthermore, it has a net charge of 4 and a pi = 10. The phase diagram of GMO-somatostatin at 20°C, clearly shows an increase of the solubility of somatostatin when for u- lated in the cubic phase. The cubic phase regions extend towards the wet region meaning that the curvature of the cubic phase(s) is decreased as the amount of somatostatin is increased. This reflects the amphiphilic nature of somatostatin analogous to the case of GMO/poloxamer 188 or Poloxamer 407/water systems. Cubic phases corresponding to a maximum of 10 wt % of somatostatin have been studied. The limit of swelling of the cubic phase is increased by nearly 10 wt.% as well. Several two-phase samples have been observed in the cubic phase region and again there exists a complicated, yet not fully resolved, cubic meso¬ morphism. However, as with many other hydrophilic proteins and polypeptides, we can conclude that the "average" cur¬ vature of the bilayer in the cubic phase is decreased as an effect of increased surface area of the apolar/polar interface caused by the presence of somatostatin. In line with this Q 229 phase has been observed. We have also investigated the phase behavior at 37°C, which shows the marked decrease of the extension of the cubic phase at lower curvatures, i.e. higher amount of water. Again analogously to the results for the GMO/poloxamer 188/water system. As seen a clear change of the phase boundaries toward the "dry" region is obtained and this is compatible with an increased curvature as expexted.

3.1.2.3. Freeze-fracture electron microscopy study

We have also investigated the homogenized disper¬ sions, prepared by methods a) and b) given in section 3.1. and 3.1.1. and homogenized as described in section 3.3.1., with freeze-fracture electron microscopy (FFEM) in colla- boration with W. Buchheim, Dept. of Chem. Phys., Federal Dairy Research Centre, Kiel, Germany. Representative micrographs show the characteristic pattern of a cubic

SUBSTITUTESHEET phase enclosed in regular shaped particles, often with square or rectangular cross-sections. The results are revealing, showing particles with a very characteristic appearance, and the structure of cubic phase is clearly seen. The periodicity of the cubic phase can be estimated to be about 150 A, in good agreement with the X-ray data. Furthermore, the average particle size is estimated to be 300 nm, which is in the same range as obtained by the light scattering experiment (see section 3.1.2.5. ) . From the largest particles (about 2 μm) a shift between adja¬ cent fracture planes corresponding to half the periodicity could be seen, which indicates that the structure is body- -centered, in agreement with the X-ray data.

The same results were obtained in the investigation of a fragmented unhomogenized somatostatin cubic phase, used in section 4.1.4.1.

3.1.2.4. 31P-NMR study

In order to investigate and further support the structural evaluation of the particles claimed an NMR investigation was performed. Dispersions were studied by 31P-NMR by means of which it is possible to differentiate between samples giving isotropic line shapes and those giving anisotropic shapes. The latter is characteristic of the lamellar and hexagonal phases, and the former of several isotropic phases, among them the cubic phase and isotropic solution phases. If the sample is a mixture of two (or more) phases, the NMR spectrum is considered to be a superposition of the individual signals (cf. Lindblom and Rilfors 1989). It is important to note that NMR is a nondestructive method in the sense that it does not need separation of the individual phases.

Both homogenized and crude dispersions as obtained by the procedures given in sections 3.1. and 3.1.1. and sub- sequently homogenized by the procedure outlined in 3.3.1. were used. No significant difference could be observed between the two dispersions. Representative powder-type

SUBSTITUTE SHEET spectrum was recorded at resonence frequencies of 40.508 MHz on a modified Varian XL-100-15 spectrometer operating in a pulsed Fourier transform mode. Only two rather close ly located peaks, with an area relation of 2:1, of narrow bandshape were observed. This indicates the presence of fast isotropic motion i.e. isotropic phases. Even if it i tempting to assume that these peaks correspond to the cubic and L3 phases, it is important to stress that these peaks can arise from, e.g., an L2 phase or vesicles, i.e. unilamellar liposomes. However, together with the evidenc obtained with the other methods, the presence of two such "isotropic" peaks supports the structure as deduced from the FFEM and X-ray studies.

3.1.2.5. Photon correlation spectroscopy (PCS) study

Homogenization of the coarse dispersion as de¬ scribed in section 3.3.1. results in a dispersion which shows enhanced colloidal stability, mainly because the reduction of particle size. Light scattering experiments (performed with a Malvern PCS100 spectrometer (Malvern

Instruments Ltd. , UK) equipped with an argon-ion laser and K7032-OS correlator) indicated that the mean particle size was about 200 - 1000 nm, depending on the pressure, number of passages and temperature during the homogenizer used in the experiments, as described in section 3.3.1. A repre¬ sentative size distribution of a homogenized dispersion shows the presence of very few particles bigger than 1 μm and about 90-95% of the particle size lies in the interval of 150-500 nm with a mean of about 300 nm. This is in agreement with the results obtained by FFEM (see section 3.1.2.3.).

3.2. L3 phase dispersions

These particles have been obtained through lyotropic phase transformation of the cubic phase dispersions de¬ scribed above. That is, the procedure is substantially the same, but the intention is that due to the existence of an

SUBSTITUTE SHEET L3 phase in equilibrium with diluted solution (knowledge of which is obtained through prior phase diagram studies) the particle interior will be an L3 phase rather than a cubic phase. Systems where an L3 phase is known to appear in equilibrium with diluted solution are ternary systems containing amphiphilic proteins, such as the casein/mono- glyceride/water system, and the poloxamer 407/monoglyce- ride/water and poloxamer 188/monoglyceride/water systems. The addition of lecithin, such as SPC, egg yolk lecithin, or lamellar forming cationic surfactants such as DDAB according to the above procedures may favor the formation of these particles over the cubic phase particles, as may the increase in the concentration of the third, amphiphi¬ lic component. Thus, the production procedures are simila to those described for fragmentation of cubic phases with the exception of procedure c) in section 3.1. The L3 phas particles are composed of bicontinuous L3 phase interiors stabilized by the action of the palisades created as de¬ scribed in a) and b) in section 3.1. In summary some of the most important fragmentation agents can be found within the following groups of compounds:

POLYMERS

Amphiphilic polymers: amphiphilic block copolymers: amphiphilic di- and tri-block copolymers: pluronics (polyxamers) and tetronics: poloxamer 407 (Pluronic® F127), poloxamer 188 (Pluronic® F68); polyvinylpyrrollidine (PVP) amphiphilic proteins: glycoprotein, casein lipopolysaccharides: Lipid A and derivatives, analogs to Lipid A, and derivatives thereof.

diacyl lipids with polymeric polar heads.

Amphiphiles, including lipids, and lipid-like surfactant and derivatives thereof

SUBSTITUTE SHEET Nonionic: polyethyleneoxide surfactants: n-alkylpolyglyco ethers (C.EO. ); various derivatives of polyoxyethylene (POE): POE fatty amine, POE glycol monoethers, POE fatty ester, POE fatty alcohol; polysorbates; sorbin esters.

Anionic: alkylsulfates; soaps; sulfosuccinates.

Cationic: quaternary ammonium compounds (cationic soaps): cetyltrimethylammonium bromide (CTAB), didodecyldimethylammonium bromide (DDAB) etc.; N-[l-(2,3- dioleoyloxy)propyl]-N, N-trimethylammonium chloride (DOTMA) and various analogs; cationic headgroup derivatives of monoacyl- or diacylglycerol.

Zwitterionic: phospholipids: phosphatidyl-choline (PC), - ethanolamine (PE), -serine (PS), -glycerol (PG): dioleoylPC (DOPC), dioleoylPE (DOPE), dioleoylPG (DOPG) (All C18:l alkyl chains, but there are many other examples and combinations); alkyl betaine derivative.

Lipid derivatives: polyethyleneglycol derivatized (phospho)lipids (PEG-PC and PEG-PE); ethoxylated cholesterol.

Glycolipids: mono-, di- and polyglycodiacylglycerols.

3.3. Aftertreatment and additional processing

Depending on the desired properties of the final for- mulation, selected in view of the particular application, various aftertreatment processes may be desired. Particles made according to procedure b) section 3.1. can be homo¬ genized with preserved structure by means of suitable equipment, such as a valve homogenizer, so as to achieve a certain particle size distribution. Other processes such as sterilization by means of an autoclave, sterile filtra¬ tion, or radiation techniques, or combinations thereof,

SUBSTITUTESHEET may be applied with preservation of the intraparticle structure and of the physicochemical state of the active compound, as now described.

3.3.1. Homogenization

Depending on the system in which particles, as de¬ scribed above, have been obtained and dependent on the de sired properties, the dispersion can be homogenized so as to achieve a satisfactory particle size distribution and surface properties. The decrease of particle size in¬ creases the stability of the dispersion, with regard to settling phenomena. However, it is important not to treat the destabilization processes with normal procedures for emulsion system, since the current system is not acting as such, nor can it be defined as such. The associated desta¬ bilization is treated in more detail in section 3.4.3.

After fragmentation of the cubic phase the dispersion may have different surface characteristics depending on the fragmentation agents used. This in turn affects particle size and properties such as adhesiveness, and it can be advantageous to homogenize the dispersion for re¬ duction in particle size and a narrow particle size dis¬ tribution. In particular, homogenization is important in the use of the current particles as drug delivery system. In practice several different homogenizers may be used; however, the introduction of new equipment requires a thorough structural evaluation so as to insure that the particles still have the intraparticular properties of the cubic phase as described above. In this work we have used two principle devices to homogenize the dispersions: an ultrasonic device and a valve homogenizer. The homogenizer used is described in detail by Thornberg and Lundh (1978). Briefly it is a pneumatic continuous valve homogenizer for laboratory use equipped with a heat exchanger and a valve. Its capacity can be varied as well as its pressure, which can be monitored. Usually, batches of 10-50 ml was conti¬ nuously homogenized at 25°C, with pressures applied in the

SUBSTITUTESHEET range of 80-180 kBar. The dispersion was carefully inves¬ tigated during and after the homogenization.

Preparation of homogenized dispersions used for FFEM, 31P-NMR, and PCS studies: A batch of the GMO/water cubic phase was prepared, sealed and stored under nitrogen atmosphere at room temperature. The water content was checked by frequent ocular examination. Normally disper¬ sions were prepared in samples of 30 ml, with a total lipid composition of 10 w/w %, and final concentrations of the GMO/SPC/poloxamer 407 system of 6.5/3.5/1.0 w/w %, st. These dispersions were prepared with the GMO/water cubic phase as starting material for the dispersions. A suitable amount of the GMO/water (65/35 w/w %) cubic phase was weighed into a ordinary beaker and mixed with appropriate amounts of a premixed dispersion of poloxamer 407 and SPC in accordance with the final concentration. The mixture was stirred for some hours until the coarse dispersion was suitable to homogenize. The homogenization was carried out at 25°C in continuous laboratory valve homogenizer, described in detail by Thornberg and Lundh (1978).

Immediately after homogenizing the dispersions were col¬ lected in 12 ml ampoules which were filled with nitrogen and flame sealed. All dispersions were stored at room temperature. The increase in stability is indicated by the fact that ultracentrifugation at 250,000xg (20°C, 24 hr) was not enough to separate the pases satisfactorily as compared to 40,000xg (20°C, 24 hr), at which a coarse dispersion of a corresponding sample was separated. By examination of samples after each passage through the valve, both in the microscope and by X-ray experiments, performed after separation of the dispersion by means of an ultracentrifuge, it was deduced that no apparent changes of the structure, other than size reduction, had occured.

SUBSTITUTE SHEET All the steps of the dispersion procedure were carefully followed by ocular inspection and by light microscopy observations, looking for signs of birefrin¬ gence and estimations of the particle size. The stability of the dispersions was judged by ocular.inspection.

3.3.2. Sterilization

Due to the stablization by the fragmentation agent, the sterilization method has to be carefully established for each system under investigation. Particles of the cubic phase dispersion type stabilized with poloxamers according to above might, however, be sterilized by seve¬ ral methods without affecting the final structure or the physical properties of the particles. This is due to the very high inversion temperature and the very high cloud point temperature (or lack thereof) for these amphiphilic block copolymers. Similar properties can be found to be valid for other block copolymers listed as fragmentation agents above. Thus, these formulations can be sterilized by autoclaving techniques with the consideration of per- oxidation carefully evaluated and taken into account.

For the majority of dispersed systems sterile filtra¬ tion is the only currently acceptable method available. Techniques such as those suggested and currenctly used in the field of biotechnology, in particular liposome and emulsion technologies can be used in connection with the current invention.

3.3.3. Further stabilization Destabilization procedures due to the colloidal nature of the current particles may in principle be avoided by the same methods used in other colloidal sys¬ tems, such as emulsion and dispersion technology. In particular, addition of polymers such as alginates, amylo- pectin and dextran, may enhance stability, as well as the use of steric stabililizing fragmentation agents.

SUBSTITUTESHEET 3.3.4. Freeze drying

Protein cubic phases can be freeze dried with re¬ tained protein structure (enzyme activity) after reconsti tution (Ericsson 1986). Thus, disclosed structures as reported here can also be freeze-dried and reconstituted. Such preliminary results have been performed and X-ray diffraction data show no significant difference between the original dispersion and the reconstituted dispersion. In particular, such procedures as freeze drying can be performed with cubic phases containing substantillay amounts of sugars, such as (Sδderberg 1990) which is thought to protect the tertiary structure of proteins and possible other compounds as nucleotides.

3.4. Variations of methods of preparation

Formulations such as those exemplified above in general may have to be modified and processed in such ways that formulations fulfil the criteria set by the govern¬ ment. In particular, additives, such as glycerol, sucrose, phosphate buffers and saline in relevant concentrations, to the aqueous compartment or formulations thereof can be added wihtout changing the principle structure of the par¬ ticles.

A particular feature of the dispersion made by method a) section 3.1. is that it is stable with the same prin¬ ciple intraparticle structure within a pH range of appro¬ ximately 2-9. Similar pH stability ranges can be expected for other non ionic systems. The addition of charged lipid species, or active ionic compounds, in the formulation can thus be used as a pH sensitive releasing/triggered system.

3.4.1. Solvent-based methods

The processes described in sections 3.1. and 3.2. can be varied according to the following: by solvent solu- bilization of the components corresponding to the consti¬ tution of the cubic phase as described in 3.1 and 3.2 or such solubi'lizate plus bioactive agents as described in

SUBSTITUTESHEET setion 4, or such solubilizate with or without bioactive component plus fragmentation agent as described in sec¬ tions 3.1 and 3.2. Solvents that can be used are, DMSO, carbontetrachloride, ethanol, methanol, hexane, or mix- tures thereof. After subsequent evaporation of the solven a cubic phase is formed. Evaporation can be achieved by conventional methods such as a rotavapor. Similar methods currently in use in the field of liposome preparation technology can in principle be applied to the current in- vention. The cubic phases are subsequently treated as described in section 3.1. for the formation of the disper sions through fragmentation of the phase constituting the interior phase, or section 3.2. for the formation of the L3 phase dispersion.

3.4.2. Dispersions with polymerizable lipids or lipid-lik surfactant

Another possibility that lies within the scope of this invention is afforded by cubic phase-forming surfac- tants, lipids, and amphiphilic monomers that can be poly¬ merized. In particular, those techniques which are dis¬ closed in the following Anderson documents, concerning the polymerization of cubic and other reversed liquid crystal¬ line phases, are in principle applicable to the present invention for the establishment of a polymrized interior phase, surface phase, or both:

Anderson, D.M. (1990) Coll. de Phys. 51(23) C7-1. Anderson, D.M. and Strom, P. (1991) Physica A 176, p. 151; Anderson, D. and Strom, P. (1989 in Polymer association structures: microemulsions and liquid crystals (El-Nokaly, M.A. ed. ) pp. 204, American Chemical Society, Washington. Strom, P. and Anderson, D.M. (1992) Langmuir 8, 691.

Research has recently arisen in the literature as to polymerizable lipids that polymerize through peptide bonds. Cubic phase particles made and polymerized with such lipids could be processed in particular depolymerized - through polypeptide degradation and biosynthesis path-

SUBSTITUTESHEET ways in the body. In this way, sites of excessive or ab¬ normal polypeptide metabolism could be targeted.

The use of polymerizable (or polymerizable/depolyme- rizable) compounds as dispersing agents opens up the possibility to tailor the characteristics of the palisade layer, substantially independently of those of the inte¬ rior. In particular, with minimal effect on the cost-ef¬ fective, protein stability, and microstructure of the interior of the particles, the hydrophilic palisade could be polymerized with a resulting strong effect on the sta¬ bility and molecular recognition properties of the par¬ ticles. The release rate, and even the functional form of the profile, could be tailored in this same way, especial ly through the use of mixtures of polymerizable and non- -polymerizing agents or agents with variable numbers of polymerizable groups, establishing distinguishable laby¬ rinths through polymerization of chiral and monolayer cubic phases. In addition to triply-periodic order, an additional degree of spatial order is afforded if the two solvent networks created by the surfactant film can be in dependently treated, in a systematic way. We have men¬ tioned that more sophisticated applications of these ma¬ terials could be made possible if this distinction were possible; that this is in principle possible, and of potential importance, is clear from the use of this pro¬ perty in the prolamellar body of etiolated leaves, for example (Gunning 1967, Tien 1982). In this subsection we discussed several ways in which this might be accomp¬ lished, based on previous work of this group. As discussed in section 2.4.2, the Q 212 cubic phase structure, which has been found in the monoolein/water/ cytochrome-c system, is believed to be the same as the structure of Q 230 except that the protein is segregated into one of these networks by virtue of its stereoche- mistry; thus the cubic phase has one aqueous network and one network filled in with inverted micelles containing proteins.

SUBSTITUTESHEET 4. Applications

Especially interesting uses of the particles claimed or as prepared by the method claimed, are those uses whic are defined in the accompanying claims. These and other uses will, however, be described more in detail below.

In the area of drug delivery, the invention is parti cularly well suited, though not limited, to the formula¬ tion and delivery of hydrophobic and amphiphilic compound that have limited aqueous solubility, or are subject to undesireable degradation or non-optimal presentation to the target, especially, coformulations of nucleic acids and/or proteins with compounds related to, or needed for, the uptake, introduction or transcription, or for its enhancement, of nucleic acids. In addition, the invention is in principle well suited for intracellular targeting. The invention is well suited as an adjuvant for vaccines, such as lipopolysaccharides, particularly for peptide- or carbohydrate-based antigenic compounds and in the cofor- mulation of immunomodulators. The invention is well suite for prolonged circulation of peptidiq drugs, and more particularly it increases the therapeutic index thus de¬ creasing systemic toxicity, which is common among com¬ pounds under investigation in the treatment of cancer and in the therapy of immune disorders, such as HIV related diseases.

Thus a drug delivery system should protect the poly¬ peptide from degradation as well as increase the half-life so to achieve longer contact times for site-specific and chronospecific delivery, both extracellular and intra¬ cellular.

4.1. Drug delivery

A major obstacle for the utilization and delivery of polypeptides and proteinaceous active agents is their for¬ mulation. The simplest form of administration of these compounds is by direct injection in hypotonic medium into

SUBSTITUTESHEET the bloodstream. However, several properties of polypep¬ tides and proteins that may impede their delivery must be taken in consideration, such as their: i) physicochemical state; ii) chemical, enzymatic and physical instability; iii) short biological half-life of circulating compound; iv) potential of provoking i munological response; v) in¬ ability to be transported from the vascular compartment t extravascular sites with efficiency; and vi) the chronici- ty of their biological task. The current invention represents a novel approach that circumvents these limitations, and furthermore pro¬ vides unique means by which to achieve chrono- and site- -specific delivery, including delivery specifically to intracellular sites - that is, directly to the cell organelles responsible for the activation and control of biosynthetic pathways governing cell metabolism and dis¬ semination of genetically-derived information. The current invention is not restricted to any particular route of ad¬ ministration, and administration can be made by intra- venous, intramuscular, intranasal, ocular, sublingual, subcutaneous, oral, rectal, vaginal, or dermal routes, or regionally such as through intraperitoneal, intraarterial, intrathecal and intravesical routes.

4.1.1. Toxicological considerations

A problem with the use of homogeneous reversed cu¬ bic phases as drug delivery system is its well documented fusogenic property and as an effect it is hemolytic. The documentation is particularly well regarding monoolein (see e.g. Cramp and Lucy, Hope and Cullis 1981 and re¬ ferences cited therein). On the other hand there are re¬ ports regarding antitumor activity of certain monoglyce¬ rides (Kato et al. 1969) as well as antimicrobial effects (see e.g. Yamaguchi 1977). The current particles, prepared by the methods given in section 3.1. and 3.1.1. do not show any fusogenic activity even when the phase constitut¬ ing the interior is originating from the GMO/water cubic

SUBSTITUTE SHEET phase, as was indicated by the absence of hemolytic pro¬ ducts in mixtures of a cubic phase dispersion and human whole blood. The apparent absence of toxic effect in the animal test discussed herein also supports this conclu- sion, although clearly more testing is necessary. This apparent lack of toxicity is almost certainly due to the increased hydrophilicity of this cubic phase dispersion a compared to the homogeneous cubic phase, and through steric stabilization, both provided by the hydrophilic palisade created by the surface phase.

4.1.2. Site-specific drug delivery

It has become urgent to develop more site-selectiv and specifically targeted drugs. In particular, the very potent and often systemic unwanted actions of peptidic drugs require efficient targeting so as to avoid the otherwise extremely high doses which can cause, e.g., im- munogenic responses. Furthermore, many of the endogenous peptidic substances considered as drugs act within 1-10 nm of their site of production. Together with their variable efficiency with time of action and the fact that polypep¬ tides are rapidly metabolized, this clearly requires spe¬ cific targeting to obtain and maintain relevant dose levels. Whether this will be achieved with the use of carriers, vehicles, drug delivery systems, or the de novo synthesis of macromolecular therapeutic systems is still an open question. Site-direction in drug delivery can be obtained by using the endogeneous routes offered. These have only been partially mapped today and perhaps the most explored pathway to obtain site selectivity has been to use monoclonal antibodies. The surface phase of the par¬ ticles of the current invention can in principle be tailored so as to be used in all kinds of different interactions with e.g. tissues, so as to increase the efficiency of the drug via the achievement of site-speci¬ fic delivery and thus increase its therapeutic index.

SUBSTITUTE SHEET 4.1.3. Organ selectivity

The use of sepcific fragmentation agents in the method of the current invention to achieve specific interactions with a set or subset of cells within one organ can e.g. be achieved through the use of different amphiphilic block copolymers, such as the poloxamers 407 and 188. It has also been shown that the biodistribution can be altered by the different surface properties ob¬ tained by the use of these polymers. Thus, as suggested by these works, the cubic or L3 dispersions can be directed towards, e.g., the bone marrow by applying different fragmentation agents as described in section 3. The use of carbohydrates or synthetically modified block copolymers as fragmentation agents can be used in the present inven- tion to further increase the specificity. The modification of the hydrophilic polyethyleneoxide units by conjugation with specific sugar moieties can be used as one approach.

The use of lectins (Sharon and Lis 1989) offers an attractive pathway to specific interactions with targets. It has been demonstrated that membrane bound lectins mediate the binding of both cellular and intracellular glycoproteins to membranes and in this way control the trafficking of glycoproteins. It is clear that this highly conserved and specific interaction can be used the other way around, i.e. that the glycoprotein (or only mimic thereof) is carried by the vehicle and upon recognition by the lectin interact with the target. Again the current in¬ vention offers important novel possibilites to achieve a uniform and efficient presentation and interaction with the target.

4.1.4. Delivery of polypeptides and proteins

The success of recombinant products for use as pharmaceutics will, at least in part, be dependent on pro- gress in the formulation of these products. However, due to the great variation of these products with regard to their physicochemical properties and biological action, a

SUBSTITUTESHEET their physicochemical properties and biological action, a single delivery system is very unlikely to satisfy all th desired properties. E.g. in the formulation of polypep¬ tides it is often thought that a sustained release should increase the bioavailability; however, there are many examples where a sustained release could cause toxic or immunogenic reactions due to, e.g., cascade effects. Clearly, the dose response and the dose determination rel on several complicated issues, from the development of international standards to the more basic understanding o the biochemical action of these products, and, still more intriguing, the patient dose dependence. Depending on the time and duration of their interaction with the target, the range of effects also might be selective. Thus, chro- nospecificity is also to be considered, particularly in the delivery of peptide hormons or neuropeptides.

For some polypeptides a duration of their delivery and a prolongation of their biological half-life may be o relevance and increase the bioavailability and/or effi- ciency. Currently most formulations of polypeptides have been concerned with the rather trivial question of in¬ creasing the biological half-life upon administration. Preparations such as liposome-associated polypeptides hav been used to sustain the delivery of many polypeptides through various routes, and to some extent it has been shown that the delivery of intact and bioactive polypep¬ tides can be prolonged for days and possibly longer. How¬ ever, very few of these studies have been at all concerned with the therapeutic efficiency of the delivery. This aspect will, however, determine whether products as lipo¬ somes will be of medical or commercial importance in a specific application. The numerous obstacles to the efficient delivery of polypeptides and proteins have been considered by many authors (Sternson 1987, Lee 1988, Eppstein and Longenecker 1988, Banga and Chien 1988).

SUBSTITUTESHEET Peptidic drugs comprise a broad class of pharmaceu¬ tics and the in vivo actions of these compounds, whether administered or endogenous, include a wide range of effects; due to their interactions, these are intrinsical ly coupled, and therefore some of the peptidic drugs are treated separately elsewhere in this text. Thus to under¬ stand and control systemic effects, site-specific deliver must be considered along with the above-mentioned conside¬ rations. Coformulations of absorption enhancers such as bile acids, for example sodium glycocholate and deoxycholate, as nonionic polyoxyethylene ethers and derivatives of fusidic acid such as sodium taurodihydrofusidate, or a combination of these, are easily achieved with the current invention.

For some peptidic compounds precautions have to be taken to avoid precipitation, fibrillation, and/or aggre¬ gation of the compound. In the current invention such changes are most conveniently avoided by adding the pep- tidic compound as a solution to a preequilibriated cubic phase with the smallest possible amount of water within the cubic phase region so as to swell the cubic phase to the cubic phase considered for the final equilibration and subsequent fragmentation, or by adding the peptidic solu- tion to a preequilibriated mixture of lamellar and cubic phase, i.e. to a two-phase region consistent with the co¬ existence at equilibrium conditions of lamellar phase and cubic phase in accordance with phase behavior, followed by equilibration and subsequent fragmentation. The latter is exemplified in the GMO (or MO or mixtures of monoglyce¬ rides or mixtures of certain monoglycerides and phospho¬ lipids or lecithin)/water system.

Examples of peptidic compounds which can be formu¬ lated with the current invention are: bovine serum albumin (BSA), insulin, epidermal growth factor (EGF), gonado- tropin-releasing hormone, interferons (type I and II; Iralfa (15-20 different species) and beta; II: gamma),

SUBSTITUTE SH ET luteinizing hormone, vasopressin and derivatives, soma¬ tostatin and analogs. Other peptide-based pharmaceuticals that are active in the cadiovascular, CNS, and gastroin¬ testinal regions, as well as those modulating the immune system or the metabolism can be formulated either alone o in mixtures by the current invention.

4.1.4.1. Example of intravenous somatostatin formulation in the rabbit Somatostatin is an endogenous small polypeptide with a wide range of biological effects which have been subject to intensive research activity since it was dis¬ covered in 1968. The very broad spectrum of actions of somatostatin have led to an immerse search for therapeutic applications. However, because of its low biological half- -life, great efforts have been put into the development of more stable and specific analogues more suitable for cli¬ nical applications.

In order to investigate the properties of cubosomes as a drug delivery system, a somatostatin loaded cubic phase dispersion preparation was studied in the rabbit using intravenous bolus injection. After injection, blood was sampled at regular intervals, and concentrations of somatostatin were determined as the specific immunoreac- tivity in plasma. It is important to note that these measurements do not reveal the amount released, and the amount of somatostatin measured can very well be located in the cubosomes. This is a common analytical problem shared by other drug vehicles. The result showed a sig- nificantly increased and maintained somatostatin concen¬ tration in the plasma within the time of the experiment which was six hours. Also shown is the plasma concentra¬ tion after bolus injection of the peptide. From these results we can conlude that the cubosomes exhibit a pro- longed circulation time. This can tentatively be explained by the palisade of PEO-units which increases the hydrophi¬ licity. This effect has been observed for other colloidal

SUBSTITUTESHEET drug carriers covered with a surface layer of poloxamer. In fact several studies have used poloxamers to prolong the circulating time of colloidal particles via an adsorp tion of the block copolymer to the surface of the partic- les, resulting in an increased hydrophilicity of the par¬ ticle surface (cf. Jamshaid et al. 1988 and references).

4.1.4.2. Example of intranasal insulin formulation in the rat Insulin (Actrapid, Novo, Denmark) has been formu lated by the current invention and delivered intranasally in a rat. Insulin solution with the desired concentration was added to samples of GMO/water, corresponding to the two-phase region where the lamellar and cubic phase (Q 230) coexist, following equilibration to insure the formation of the desired cubic phase used for subsequent fragmenta¬ tion. SAXS methods were used to insure that the formula¬ tion prior fragmentation correspond to a cubic phase. Fragmentation was performed as described in section 3.1 method b) as described in detail in section 3.1.1. All steps in the formulation procedure were performed under antiseptic conditions. In the current example with regard to route of administration and the delicate properties of insulin the fragmented colloidal dispersion was chosen not to be further processed. There were no signs of instabili¬ ty of the dispersion during the time of the experiments (approximately 2 months).

Animal experiments were performed in collaboration with Dr. P. Ederman, Dept. of Pharmacy, Uppsala Univer- sity. The formulation (10 IU/ml) was administered intra¬ nasally in rats (Wistar) and the change in the blood glu¬ cose was used as a measure of the insulin delivery through the nasal epithelia. A significant change was observed and o obvious signs of side effects were observed.

SUBSTITUTESHEET 4.1.5. Adjuvant formulations and the use of the current particles as a vehicle for immunomodultative compounds

The development of specific recombinant or synthe- tic antigenetic substances, such as subunit antigen and polypeptides, have lead to an urgent need for vaccine ad¬ juvants since these structures are generally of low anti- genicity. Therefore their promise as vaccines will rely o their formulation with adjuvants that increase cell-me- diated and humoral responses (Alison and Byars 1990).

The two most often considered lipid-based colloidal vaccine adjuvants are liposomes (Allison and Gregoriadis 1974, Gregoriadis 1990) and Freunds adjuvants (Edelman 1980). Lately, however, the use of liposomes as adjuvant systems has been reconsidered and as pointed out by Weine (Weiner 1989) liposomes do not insure an increased immune reactivity. The properties and features of some new adju¬ vants for vaccines have been reviewed (Eppstein et al. 1990). It has become clear that the presentation of the an¬ tigenic structure is of great importance for the immune reactivity, response and the subsequent development of immunity and that membrane perturbations are of profound importance in immunogenic responses. Even though not ge- nerally accepted it is believed that the events upon mem¬ brane perturbations are intimately connected to the re¬ quired intracellular enzyme activity and that the ra¬ tionale for this is the cooperative biogenesis of intra¬ cellular membranes and especially the expression and surface properties of the plasma membrane. It is therefore very interesting to note that the biological active part of different lipopolysaccharides (LPS), Lipid A, forms a cubic phase in excess of physiological solution at physio¬ logical conditions (Brandenburg et al. 1990) and thus behaves very similar to the monoolein-water system. It can also be fragmented by the methods given in section 3 and used either alone or with solubilized vaccines and/or

SUBSTITUTE SHEET other immunomodulating compounds. Lidid A and synthetic analogous have frequently been used in adjuvant formula¬ tions for immunostimulation. It is therefore to be con¬ sidered that coformulations of monoolein-lipid A forming cubic phase in excess of solution would elicit strong immunogenic response. Other coformulations either with GMO, Lipid A or a combination of these, are with saponins (Barla et al 1979), bile acids (Lindstrom et al. 1981, Svard et al. 1988), phospholipids (Gutman et al. 1984) and diacylglycerols.

In particular, the particles of the current invention are suitable as an adjuvant for polysaccharide antigens. It is well established that adjuvants, such as LPS's and muramyl dipeptide (MDP), induce the production - by accessory cells - of mediators, such as interleukin-1 (IL- 1) and other lymphocyte growth factors, stimulating the proliferation of helper T-lymphocytes. The importance of the targeting of antigens to highly efficient presenting cells, such as interdigitating and follicular dendritic cells, has been emphasized (Allison and Byars 1986). Thus, procedures that facilitate the migration of antigens to the paracortical areas of lymph nodes, in the immediate vicinity of interdigitating cells, should favor cell-me¬ diated immunity. The particles of the current invention could thus be transferred to precursors of interdigitating cells at the site of injection, in afferent lymph or in lymph node sinuses.

Similarly, any procedure, such as selective receptor targeting directed towards C3b receptors on B-lymphocytes, that facilitates localization of antigens on follicular dendritic cells should increase B-lymphocyte responses.

Therapeutics which have been investigated as diffe¬ rentiating or inhibiting compounds are very attractive candidates to formulate by the current invention. In par¬ ticular, peptidic drugs such as oligopeptides may act in the inhibition of EGF receptor. Similar approaches are

SUBSTITUTE SHEET currently investigated in the treatment of the acquired immunodeficiency syndrome (AIDS), a subject dealt with in section 4.1.7.1. Another potential application is the coformulation of the antigen and/or immunomodulator with cytostatic drugs such as methotrexate, so as to potentiat the immunogenic response and/or decrease or diminish po¬ tential immune responses to antigens in antibody-targeted applications of the current invention.

4.1.6. Cancer therapy

The current invention should be applicable to the field of cancer therapy. As to further details in this context reference is made to the use of liposomes for suc purposes (see e..g. Weinstein 1987).

Preferential delivery to tumors is a challenge that, if solved, would represent an enormous advanve in cancer therapy. Reduced systemic concentrations of the drug bein delivered is a step is this direction, and by applying th methods described in section 4.1.2. and 4.1.3, site selectivity could in principle be realized. Lipid biogenesis and the role of lipids as second messengers in the development of cancer has drawn increased research interest and activity. Coformulations of anticancer drugs and such second messengers can easily be accomplished by the current invention.

The rationale for use of lipid-based vehicles in general, and the current invention in particular, as carriers in chemotherapy is based on the following basic concept: prolonged circulation as compared to the free drug; protection and stabilization of the drug; circumvention of certain cell membrane barriers; amplification of the drug effect due to targeted drug delivery. Agents of particular interest in this connection are: doxorubicin; taxol; alόpacia; cisplarin derivatives; and vincristine.

SUBSTITUTESHEET 4.1.7. Antimicrobial therapy

The potency of drugs used against microbial infec¬ tions, i.e. bacterial/rickettsial, parasitic and viral infections, can be correlated with their lipophilicity. The more lipophilic the more potent. Thus, the current system can solubilize large amounts of potent antimic¬ robial agents and at the same time protect or minimize the host from systemic toxic effects.

Many of the new antimicrobial drugs under considera- tion are of proteinaceous type. Some of these polypeptidic drugs considered fall also in the category of immunomodu¬ lators, such as some interferons. Further examples in this category are lymphokines for the treatment of visceral leishmaniasis, and cytokines; ampicillin for the treatment of intracellular liver and spleen infections caused by

Listeria monocytogenesis; amphotericin B in the treatment of mycotic infections; ribavirin for the treatment of fever virus infecton; streptomycin for the treatment of tubercolosis and splenic infections; sisomycin for the treatment of lung infections; gentamicin for the treatment of intraperitoneal infection; and penicillin G for the treatment of intraperitoneal extracellular infection caused by Staphylococcus aureus. Applications where sus¬ tained release are of particular interest are in the treatment of genital papilloma virus infections. Coformu- lations of lipophilic, amphiphilic and hydrophilic antimicrobial drugs can be achieved with the current in¬ vention. Such formulations find their application in the treatment of patients of systemic microbial infections, which often is the case for patients having AIDS.

4.1.7.1. Therapy of human immunodeficiency virus-related disease

The potential for the use of the present partic- les in a delivery system for therapeutic intervention in therapy of human immunodeficiency virus (HIV)-related disease, especially acquired immunodeficiency disease

SUBSTITUTE SHEET (AIDS), follows from their potential in polypeptide and protein delivery, in the delivery of immunomodulative compounds, and in intracellular targeting and delivery of such compounds, as discussed herein. Of particular impor- tance in this respect is their potential use in the modu¬ lation of lipid biogenesis and the subsequent membrane formation, as target for the treatment of, e.g., cancer and other hyperactive cells such as virus-infected cells. Selective drug delivery is important to cells which are infected or to cells which are known to be targets for HIV infection, such as CD4+T cells, certain types of B cells, monocytes/macrophages, dendritic cells, Langerhans cells, and some brain glial cells, as well as HIV infects CD8+T cells, muscle cells, fibroblastoid cells, and some neuronal cells in vitro. Thus, all these, and other, cell types are potential targets for the current particles. Indeed, the same rationale as outlined for the targeting of immunomodulators and vaccine formulations are valid in most, in particular, the high surface area and the ability of coformulation.

The formulation of drugs or the use of fragmentation agents or part thereof which binds to target cells or pre¬ ferably HIV, thus enables inhibition of gp 120 induced cytocidal effect. Such compounds are CD4 analogs and anti- bodies to HIV. The use of the current particles benefits such interactions needed and their prolonged circulation increases these interactions.

The (site specific) delivery of reverse transcriptase inhibitors, such as 3 'azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside analogs such as ddl, d4T and AZddu using the current nomenclature, dipyridodiazepinone derivatives and tetrahydro-imidazo[4, 5, 1-j ,k] [1,4]-benzo- -diazepin-2(lH)-one (TIBO) and -thione(tibo) and deriva¬ tives. The (site specific) delivery of specific inhibitors of HIV ribonuclease H (RNase H) activity, inhibitors of transcription and translation of the virus encoded repli-

SUBSTITUTE SHEET cation.

Formulations with compounds that block the processin of the virus envelop glycoprotein gp 120 and/or gp 41 or their precursor, such as N-butyl-nojirymycin. Coformulations of certain immunomodulators or indu- cers thereof such as interferons, in particular IFN-gamma, with other compounds used in the treatment of HIV infec¬ tions.

4.1.8. Gene therapy

The rationale of gene therapy has been discussed by many authors (cf. Wilson 1986) and the field appears to have a high potential. It is very likely that the effi¬ ciency and stability of the introduced gene will depend on its specific delivery to the target cell and on intra- cellular interactions. For example, in the treatment of bone marrow cells, an extraordinarily efficient and selec¬ tive delivery is required since stem cells of the bone marrow only comprise about 0.001-0.01% of the total cells. The task to be solved by the delivery system for in vivo targeting is therefore considerable. The current invention offers not only a very high solubility of DNA fragments and/or plasmids but also protects DNA from undesireable interactions with body fluids.

4.2. Biotechnological and biomedical applications

The considerable direct, and indirect, evidence for the high enzymatic activity in the cubic phase particles of this invention, together with their versatility in the immobilization of enzymes at high loadings make the cur¬ rent invention advantageous as compared to current avail¬ able immobilization units in biotechnology. This has been discussed in the case of homogeneous cubic phases by Anderson (1987), and the current invention represents an improvement of that invention because of the much higher surface/volume ratio in submicron particles of the cubic phase, thus facilitating access into and out of active

SUBSTITUTE SHEET sites. The use of lipid-based vehicles in imaging, in particular liposomes as contrast-enhancing agents or in diagnostic nuclear medicine have been reviewed (Weinstein 1987, Caride 1985). Applications of the current particles in diagnostic imaging are as carriers of radiological con trast agents.

Delivery of oxygen can be achieved by the preparatio of an oxygen carrier, such as the heme group in hemoglobu lin or similar protein, in a cubic phase. Cubic phases in the system hemoglobulin-GMO-water have been investigated and are formed with high amounts of protein (>5 wt.%). Such a system can be used as blood substitute and in connection with radiation therapy of cancer. The use of polymerizable lipids, in such systems as described above could be used to enhance stability and shelf-life.

4.2.1. Transfection technology

The present invention should also be useful in the fields of transfection technology, i.e. the introduction of foreign nucleic acids into cell types/lines. Particu¬ larly, in view of the currently used liposomal system for the use in this field, such as DOPE which is a prominent non-lamellar forming lipids in aqueous systems, and the fact found by the inventors that the current particles ca be formed in the GMO/DDAB/water system (see section 3.1.1. ).

4.2.2. Cell culture

The invention should also be useful in the field o cell culture, especially use of the particles as carriers of nutrients, such as amino acids, cholesterol, unsatu- rated fatty acids, but also as delivery systems for more sepcific proteins as immunomodulators, growth factors etc., or for the use as diagnostics, biosensor, in immuno assays in cell culture. Also in the field of cell hybri- doma technology applications are possible.

SUBSTITUTE SHEET 4.3. Other applications

The present invention should also be applicable to other areas, in particular applications in the area of biosensors and as catalytic particles or carriers of catalysts. Other biomedical and biotechnological areas include enzyme therapy (as with superoxide dismutase), dispersions with magnetic properties, immobilization of the particles in gel matrices. These particles can also provide sites for mineralization and crysatallization. Mineralization of a substantial portion of the porespace or porewall surface could create microporous particles with high chemical and thermal stability, and the use of conducting or piezoelectric minerals or crystals could be important. The presence of polar groups at the porewall surface makes these particles particularly well suited for mineralization.

The present invention will also find cosmetic appli¬ cations. Indeed examples of the molecular constituents of the particles such as monoglycerides and poloxamers are frequently encountered in cosmetic preparations.

A curious phenomena found by the inventors is the capability of certain cubic phases, such as those formed in the GMO/poloxamer/water systems described above, to host fungi and also supply needs for their growth. Perhaps, most surprisingly the cubic phase maintains its characteristics up to several months before phase trans¬ formation takes place. Thus the fungi grow inside the cubic phase without perturbing its structure. Therefore, the current particles could be utilized as culture media/machinery for the controlled culture of single, or multiple microorganisms.

SUBSTITUTE SHEET 5. References

Allison, A.C. and Byars, N.E. (1986) J. Immunol. Methods,

95, 157. Allison, A.C. and Byars, N.E. (1990) in New generation vaccines (Woodrow, G.C. and Levine, M.M. eds. ) pp. 129-

140, Marcel Dekker, New York.

Allison, A.C. and Gregoriadis, G. (1974) Nature, 252, 25

Alving, C.R. (1987) in Liposomes from biophysics to ther peutics (Ostro, M.J. ed. ) pp. 195-218, Marcel Dekker, Ne

York.

Anderson, D.M. (1987) U.S. Patent Appln. #07/052,713; EPO

Appl. 88304625.2; Japanese Appl. 63-122193; U.S. Patent

Appl. #07/500,213 (1990). Anderson, D., Wennerstrόm, H. and Olsson, U. (1989) J.

Phys. Chem. 93,4243.

Banga, A.K. and Chien, Y.W. (1988) Int. J. Pharmac. 48,

15.

Barla, P., Larsson, K., Ljusberg-Wahren, Norin, T. and Roberts, K (1979) J. Sci. Food. Agric. 30, 864.

BASF (1989) "Performance chemcials FDA and EPA status information bulletin", Parsippany, USA.

Benton, W.J. and Miller, CA. (1983) J. Chem. Phys. 73,

4981. Bergenstahl, B. and Fontell, K. (1983) Prog. Colloid

Polym. Sci. 68, 48.

Brandenburg, K. , Koch, M.H.J. and Seydel, U. (1990) J.

Str. Biol. 105, 11.

Burrows, R. , Attwood, D. and Collett, J.H. (1990) J. Pharm. Pharmacol. 42, suppl. Science proceeding 127th meeting of the British Pharmaceutical conference 1990,

Abstract 3P.

Byars, N.E. and Allison, A.C. (1987) Vaccine, 5,223.

Caffrey, M. (1989) Biophys. J. 55, 47. Caride, V.J. (1985) Crit. Rev. Ther. Drug Carrier Sys. 1,

121.

Cosmetic Ingredient review (CIR) (1986) J. am. Toxicol. 5

SUBSTITUTE SHEET 391.

Cramp, F.C. and Lucy, J.A. (1974) Exptl. Cell Res. 87, 107.

Davis, S.S., Hadgraft, J. and Palin, K.J. (1983) in Encyclopedia of emulsion technology (P. Becker, ed. ) Vol. 1, pp. 159, Marcel Dekker, New York. Dubois, M. and Zemb, T. (1991) Langmuir 7, 1352. Edelman, R. (1980) Rev. Infect. Dis. 2, 370. Ekwall, P. (1975) in Adv. Liq. Cryst. (Brown, G.H. ed. ) 1, 1.

Engstrom, S. (1990) Lipid Techn. 2, 42.

Engstrom, S. and Engstrom, L. (1992) Int. J. Pharmac. 79, 113.

Engstrom, S., Larsson, K. and Lindman, B. (1983) EPO patent 0 126 751; PCT/SE83/0041.

Eppstein, D.A. and Longenecker, J.P. (1988) CRC Crit. Rev. Ther. Drug Carrier Sys. 5, 99.

Eppstein, D.A., Byars, N.E. and Allison, A.C. (1990) Adv. Drug Del. Rev. 4, 233. Ericsson, B. (1986) Ph.D. Thesis, Lund University, Sweden. Ericsson, B., Eriksson, P.-O., Lδfroth, J.-E. and Engstrom, S. (1991) in Polymeric drug and drug delivery systems (R.L. Dunn and M. Ottenbrite, eds. ) ACS Symp. Ser. 469, Am. Chem. Soc. Ericsson, B., Larsson, K. and Fontell, K. (1983) Biochim. Biophys. Acta, 729, 23.

Fontell, K. (1974) in Liquid crystals and plastic crystals (Gray, G.W. and Winsor, P.A. eds. ) vol. 2, pp. 80-109, Ellis Horwood, Chichester. Fontell, K. (1978) Progr. Chem. Fats Lipids 16, 145. Fontell, K. (1981) Mol. Cryst. Liq. Cryst. 63, 59. Fontell, K. (1990) colloid and Polym. Sci. 268, 264. Gazeau, D. Bellocq, A.M. Roux, D. and Zemb, T. (1989) Europhys Lett. 9,447. Gregoriadis, G. (1988a) ed. Liposomes as drug carriers. Recent trends and progess, John Wiley, New York. Gregoriadis, G. (1988b) in Liposomes as drug carriers.

SUBSTITUTE SHEET Recent trends and progess (Gregoriadis, G. ed.), pp.3-18,

John Wiley, New York.

Gregoriadis, G. (1990) Immunol, today, 11, 89.

Gregoriadis, G., Garcon, N., Senior, J. and Davis, D. (1988) in Liposomes as drug carriers. Recent trends and progress (Gregoriadis, D. Ed.), pp. 279-307, John Wiley,

New York.

Gulik, A., Luzzati, V., Rosa de, M. and Gambacorta, A.

(1985) J. Mol. Biol. 182, 131. Gulik-Krzywicki, T. (1975) Biochim. biophys. Acta 415, 1.

Gunning, B.E.S. and Jagoe, M.P. (1967) in Biochemistry of chloroplasts (T.W. Goodwin, ed. ) vol. 2, pp. 655, London,

Academic Press.

Gutman, H. Arvidson, G. Fontell, K. and Lindblom G. (1984 in Surfactants in solution (Mittal, K.L. and Lindman, B. eds.) vol. 1, pp. 143-152, Plenum Press; New York.

Hope, M.J. and Cullis, P.R. (1981) Biochim. Biophys. Acta

640, 82.

Hyde, S.T., Andersson, S., Ericsson, B. and Larsson, K. (1984) Z. Kristallogr. 168, 213.

Ibrahim, H-G. (1989) J. Pharm. Sci. 78, 683.

Kato, A., Ando, K., Suzuki, S., Tamura, G. and Arima, K.

(1969) J. Antibiotics 22, 83.

Killian, J.A. and Kruijff de, B. (1986) Chem. Phys. Lipid 40, 259.

Krog, N. (1990) in Food emulsions (Larsson, K. and

Friberg, S. eds.) pp. 127-180, Marcel Dekker, New York.

Krog, N. and Larsson, K. (1983) in Encyclopedia of emul¬ sion technology (Becker, P. ed. ) vol. 2, pp. 321-365, Marcel Dekker, New York.

Larsson, K. (1989) J. Phys. Chem. 93, 7304.

Larsson, K. , Gabrielsson, K. and Lundberg, B. (1978) J.

Sci. Fd. Agric. 29, 909.

Lee, V.H.L. (1988) CRC Crit. Rev. Ther. Drug Carriers Sys. 5, 69.

Lieberman, H.A.,Rieger, M.M. and Banker, G.S. (1989) eds. Pharmaceutical dosage forms: dispersable systems, Vol. 2,

SUBSTITUTESHEET Marcel Dekker, New York.

Lindblom, G, . Larsson, K., Johansson, L., Fontell, K. and Forsen, S. (1979) J. Am. Chem. Soc. 101, 5465. Lindblom, G. and Rilfors, L. (1989) Biochim. Biophys. Acta, 988, 221.

Lindstrδm, M. , Ljusberg-Wahren, H., Larsson, K. and Borgstrδm, B. (1981) Lipids 16, 749.

Loth, H. and Euschen, A. (1990) Drug Develop. Industr. Pharm. 16, 2077. Lundsted, L.G. and Schmolka, I.R. (1976) in Block and graft copolymerization (Ceresa, R.J. ed. ) vol. 2, pp. 1- 112, Wiley, London.

Lundsted, L.G. and Schmolka, I.R. (1976) in Block and graft copolymerization (Ceresa, R.J. ed. ) vol. 2, pp. 113- 272, Wiley, London.

Lutton, E.S. (1965) J. Am. Oil Chem. Soc. 42, 1068. Luzzati, V. (1968) in Biological membranes (Chapman, D. ed. ) vol. 1, pp. 71-123, Academic Press, New York. Luzzati, V., Gulik, A., Gulik-Krzywicki, T. and Tardieu, A. (1986) in Lipids and membranes. Past present and future (Op den Kamp, J.A.F. Roelofsen, B. and Wirtz, K.W-A. eds.) pp. 137-151, Elsevier, Amsterdam.

Luzzati, V., Mariani, P. and Gulik-Krzywicki, T. (1987) in Physics of amphiphilic layers (Meunier, J., Langevin, D. and Boccara, N. eds.) pp. 131.

Margolis, L.B. (1988) in Liposomes as drug carriers. Recent trends and progress (Gregoriadis, G. ed.), pp. 75- 92, John Wiley, New York.

Mariani, P., Luzzati, V. and Delacroix, H. (1988) J. Mol. Biol. 294, 165.

Martindale the extra pharmacopoeia (1982) (Reynolds, J.E.F. ed. ) Pharmaceutical Press, London. Meadows, G.G. and Pierson, H.F. (1988) in Liposomes as drug carriers. Recent trends and progess (Gregoriadis, G. ed. ), pp. 461-472, John Wiley, New York.

Milner, S.T., Cates, M.E. and Roux, D. (1990) J. Phys France 51, 2269.

SUBSTITUTE SHEET Morein, B. (1988) Nature 332, 287.

Morre, D.J. (1989) in The pathobiology of neoplasia

(Sirica, A.E. ed. ) pp. 323-344, Plenum Press, New York.

Mueller-Goymann, C.C. (1985) Pharmazeutische Z. 130, 682. Mueller-Goymann, C.C. (1987)Acta Phar. Technol. 33, 126

Mueller-Goymann, C. (1989) Acta Pharm. Nord. 1, 238.

Mulley, B.A. (1974) in Emulsions and emulsion technology

(K.J. Lissant, ed. ) pp. 291, Marcel Dekker, New York.

Peptide pharmaceuticals: approaches to the design of nove drugs (1991) (Ward, D.J. ed.) Elsevier, New York.

Pharmaceutical dosage forms; disperse systems (1988)

Liebermann, A., Rieger, M.M. and Banker, S. eds.) Vol. 1 and 2, Marcel Dekker, New York.

Porte, G., Marignan, J., Bassereau, P. and May, R. (1988) J. Phys. France 49, 511.

Rosvear, F.B. (1968) J. Soc. Cosmetic Chemists 19, 581.

Rydhag, L. (1979) Fette, Seifde, Anstrichtmittel 81, 168.

Sharon, N. and Lis, H. (1989) "Lectins" Chapman Hall,

London. Seddon, J. (1989) Biochim. Biophys. Acta, 1031, 1.

Small, D.M. (1986) "The physical chemistry of lipids" pp.

89-96, Plenum Press, New York.

Speiser, P. (1984) in Reverse micelles. Biological and technological relevance of amphiphilic structures in apolar media (Luisi, P.L. and Straub, B.E. eds.) pp. 339-

346, Plenum Press, New York.

Sternson, L.A. (1987) in Biological approaches to the controlled delivery of drugs. Annals of the New York

Academy of Sciences, vol. 507 (Juliano, R.L. ed. ) pp. 19- 21, New York Academy of Sciences, New York.

Stigi, J.F. and Lowery, A. (1990) in Specialized drug delivery systems (Tyle, P. ed. ) pp. 51-217, Marcel Dekker, New York.

Strey, R. , Jahn, W. , Poerte, G. and Bassereau, P. (1990a) Langmuir 6, 1635.

Strey, R. , Schomacker, R., Roux, D., Nallet, F. and Olsson, U. (1990b) J. Chem. Soc. Faraday trans. 86, 2253

SUBSTITUTE SHEET Svard, M., Schurtenberger, P., Fontell, K., Jδnsson, B. and Lindman, B. (1988) J. Phys. Chem. 92, 2261 Sδderberg, I. and Ljusberg-Wahren, H. (1990) Chem. Phys. Lipids 55, 97. Therapeutic pep ides and proteins. Formulation, delivery and targeting (1989) (Marshak, D. and Liu, D. eds.) Cold Spring Harbor, New York.

Thornberg, E. and Lundh, G. (1978) J. Food Sci. 43, 1553. Tice, T.R. and Tabibi, S.E. (1992) in Treatise on controlled drug delivery (A. Kydonieus, ed. ) pp. 315, Marcel Dekker, New York.

Tiddy, G.J.T. (1980) Phys. Reports 57, 1. Tien, H.T. (1982) in Solution behavior of surfactants (Mittal, K.L. and E.J. Fendler, eds.) vol. 1, pp. 229, Plenum Press, New York.

Tomlinson, E. (1990) in Modern pharmaceutics (Banker, G.S. and Rhodes, CT. eds.) pp. 673-693, Marcel Dekker, New York.

Tyle, P. (1989) in Controlled release of drugs (Rosoff, M. ed.) pp. 125, VCH Publishers, New York.

Weiner, A.L. (1989) Adv. Drug. Del. Rev. 3, 307. Weiner, A.L. (1990a) Biopharm. 3(2), 27. Weiner, A.L. (1990b) Biopharm. 3(4), 16. Weinstein, J.N. (1987) in Liposomes from biophysics to therapeutics (Ostro, M.J. ed. ) pp. 277-338, Marcel Dekker, New York.

Wilson, G. (1986) in Site-specific drug delivery (Tomlinson, E. and Davis, S.S. ed. ) pp. 149-164, John Wiley, New York. Yamaguchi, H. (1977) Antimicrob. Agents Chemother. 12, 16.

SUBSTITUTESHEET

Claims

1. Particles, especially colloidal particles, comprising an interior phase of a non-lamellar lyotropic liquid crys talline phase selected from the group consisting of a re¬ versed cubic liquid crystalline phase, a reversed interme diate liquid crystalline phase and a reversed hexagonal liquid crystalline phase, or a homogeneous L3 phase, or any combination thereof, and a surface phase selected fro the group consisting of a lamellar crystalline phase and lamellar liquid crystalline phase, or an L3 phase, or any combination thereof.
2. Particles according to claim 1, wherein the interior phase is selected from the group consisting of a reversed cubic liquid crystalline phase, a reversed hexagonal liquid crystalline phase and a reversed cubic-hexagonal liquid crystalline phase and the surface phase is an L3 phase.
3. Particles according to claim 2, wherein the interior phase is a reversed cubic liquid crystalline phase and th surface phase is an L3 phase.
4. Particles according to claim 1, wherein the interior phase is selected from the group consisting of a reversed cubic liquid crystalline phase, a reversed hexagonal li¬ quid crystalline phase and a reversed cubic-hexagonal li- quid crystalline phase and the surface phase is selected from the group consisting of a lamellar crystalline phase and a lamellar liquid crystalline phase.
5. Particles according to any one of claims 1 - 4, which contain added bio-active agents, or precursors thereof.
6. Particles according to claim 5, wherein said bio-
SUBSTITUTE SHEET active agent, or precursor thereof, is selected from the group consisting of peptides and proteins, or protein¬ aceous compounds.
7. A method of preparing particles, especially colloida particles, from a homogeneous liquid crystalline phase o L3 phase, which comprises forming a homogeneous, non- lamellar lyotropic liquid crystalline phase selected fro the group consisting of a reversed cubic liquid crystal- line phase, a reversed intermediate liquid crystalline phase and a reversed hexagonal liquid crystalline phase, or a homogeneous L3 phase, or any combination thereof, creating a local dispersible phase, within said homo¬ geneous phase, of a phase selected from the group con- sisting of a lamellar crystalline phase and a lamellar liquid crystalline phase, or an L3 phase, or any combi¬ nation thereof, in the presence of a solvent phase, said solvent being of a nature with which said homogeneous phase can coexist and wherein said dispersible phase can be dispersed, and fragmentating said homogeneous phase so as to form particles, the interior phase of which com¬ prises said homogeneous phase and the surface phase of which comprises said dispersible phase.
8. A method according to claim 7, wherein the local dis¬ persible phase is created by means of at least one frag¬ mentation agent which is an agent of such a nature that when combined with said homogeneous phase, or those constituents which will form said homogeneous phase, it creates said dispersible phase.
9. A method according to claim 8, wherein the fragmenta¬ tion agent is selected from the group consisting of lipopolysaccharides, polysaccharides, glycoproteins and proteins.
10. A method according to claim 8, wherein the fragmenta tion agent is selected from the group consisting of amph philic macromolecules, lipids, amphiphilic lipid-like surfactants and derivatives thereof.
11. A method according to claim 10, wherein the fragment tion agent is an amphiphilic polymer, preferably an amph philic block copolymer.
12. A method according to claim 10, wherein the fragment tion agent is selected from the following groups of amph philic lipids, lipid-like surfactants and derivatives thereof: nonionic, preferably polyethyleneoxide surfac¬ tants; anionic; cationic, preferably quaternary ammonium compounds; zwitterionic, preferably phospholipids; lipid derivatives, preferably polyethyleneglycol derivatized (phospho)lipids; and glycolipids.
13. A method according to any one of claims 8 - 12, wher in the local dispersible phase is created by a procedure according to any one of the following alternatives: a) a solution of said fragmentation agent in a polar solvent, preferably water, is added to said homogeneous phase; b) a dispersion of said fragmentation agent in a polar liquid, preferably water, is added to said homogeneous phase; or c) said homogeneous phase is fragmentated in a solution said fragmentation agent in a polar solvent, preferably water.
14. A method according to any one of claims 7 - 13, wher in the particles formed are aftertreated by means of one or more of the following procedures: homogenization, sterilization, stabilization by the addition of polymers and freeze drying.
SUBSTITU
15. A method according to any one of claims 7 - 14, where¬ in at least one bioactive agent or a precursor thereof, preferably selected from the group consisting of peptides and proteins, or proteinaceous compounds, is added at any stage of the preparation of said particles.
16. A pharmaceutical composition comprising particles according to any one of claims 1 - 6 or prepared by a method according to any one of claism 7 - 15.
17. Particles according to any one of claims 1 - 6 or as prepared by a method according to any one of claims 7 - 15 for use in a therapeutic treatment or a diagnostic method, including the use thereof as an adjuvant, especially for substained release of the active ingredient(s).
18. Use of particles according to any one of claims 1 - 6 or as prepared by a method according to any one of claims 7 - 15, for the manufacture of a medical preparation for use as an antigen-presenting system, as a colloidal drug delivery system as carrier of nutrients for parenteral delivery of nutrition, as a colloidal delivery system for anticancer drugs or as a colloidal delivery system for antifungal and antimicrobial drugs.
19. Use according to claim 18 of said particles for the manufacture of a preparation for the treatment of cancer or AIDS.
20. Use of particles according to any one of claims 1 - 6 or as prepared by a method according to any one of claims 7 - 15, for non-medical technology as carriers of nucleic acids or nucleotides.
21. Use of particles according to any one of claims 1 - 6 or as prepared by a method according to any one of claims 7 - 15, for non-medical technology as carriers in cell culture techniques, in immunoassay techniques, in immobi¬ lization techniques or for the growth of single crystals of proteins or inorganic substances.
22. Use of particles according to any one of claims 1 - 6 or as prepared by a method according to any one of claims 7 - 15, in biosensor applications or as radiation tracers
10
15
20
25
30
*
35
PCT/SE1992/000692 1991-10-04 1992-10-02 Particles, method of preparing said particles and uses thereof WO1993006921A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US77101491A true 1991-10-04 1991-10-04
US771,014 1991-10-04
PCT/SE1992/000692 WO1993006921A1 (en) 1991-10-04 1992-10-02 Particles, method of preparing said particles and uses thereof

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
DE1992629640 DE69229640D1 (en) 1991-10-04 1992-10-02 Particles, method for preparing the particles and their use
CA 2120359 CA2120359C (en) 1991-10-04 1992-10-02 Particles, method of preparing said particles and uses thereof
JP50684193A JP3571717B2 (en) 1991-10-04 1992-10-02 Particles, the particles of the preparation and use thereof
DE1992629640 DE69229640T2 (en) 1991-10-04 1992-10-02 Particles, method for preparing the particles and their use
PCT/SE1992/000692 WO1993006921A1 (en) 1991-10-04 1992-10-02 Particles, method of preparing said particles and uses thereof
US08/211,293 US5531925A (en) 1991-10-04 1992-10-02 Particles, method of preparing said particles and uses thereof
EP19930906328 EP0643620B1 (en) 1991-10-04 1992-10-02 Particles, method of preparing said particles and uses thereof
BR9206593A BR9206593A (en) 1991-10-04 1992-10-02 Especially colloidal particles Particles process of preparing them from a homogeneous liquid crystalline phase or L3 phase pharmaceutical composition and use of these particles
NO941191A NO941191L (en) 1991-10-04 1994-03-30 Particles, methods of making and using such
FI941538A FI941538A (en) 1991-10-04 1994-03-31 The particles, a process for their preparation and their use

Publications (1)

Publication Number Publication Date
WO1993006921A1 true WO1993006921A1 (en) 1993-04-15

Family

ID=26661355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1992/000692 WO1993006921A1 (en) 1991-10-04 1992-10-02 Particles, method of preparing said particles and uses thereof

Country Status (2)

Country Link
NO (1) NO941191L (en)
WO (1) WO1993006921A1 (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444041A (en) * 1991-04-19 1995-08-22 Ibah, Inc. Convertible microemulsion formulations
EP0686386A1 (en) 1994-06-08 1995-12-13 L'oreal, S.A. Cosmetic and dermatologic composition comprising a stable aqueous dispersion of phytantriol-based gel particles containing a long-chain surfactant as dispersant and stabilizer
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
WO1997047250A1 (en) * 1996-06-13 1997-12-18 Mehl Thomas L Sr Liquid crystals in dermatological treatments using light energy
WO1997047320A1 (en) * 1996-06-10 1997-12-18 Pharmatrix Ab Immunstimulating lipid formulation
US5707648A (en) * 1993-11-17 1998-01-13 Lds Technologies, Inc. Transparent liquid for encapsulated drug delivery
EP0942780A1 (en) * 1997-09-09 1999-09-22 Select Release, L.C. Coated particles, methods of making and using
WO1999047004A1 (en) * 1998-03-13 1999-09-23 Societe Des Produits Nestle S.A. Food composition containing a monoglyceride mesomorphic phase
US6071524A (en) * 1994-11-10 2000-06-06 L'oreal Oily phase in aqueous phase dispersion stabilized by cubic gel particles and method of making
WO2000047225A2 (en) * 1999-02-12 2000-08-17 Eurocine Ab Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
DE10057770A1 (en) * 2000-11-22 2002-05-23 Beiersdorf Ag Cosmetic or dermatological composition comprises dispersed liquid crystals forming a cubic phase
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
EP1331913A2 (en) 2000-06-29 2003-08-06 THE PROCTER & GAMBLE COMPANY Cubic liquid crystalline compositions and methods for their preparation
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
WO2004108884A2 (en) * 2003-06-10 2004-12-16 Anna Imberg Composite materials and particles
EP1529519A2 (en) * 2003-11-07 2005-05-11 L'oreal Cosmetic use of cubic gel particles as agents against adhesion of microorganisms to the skin and/or mucosa
US6989195B2 (en) * 1997-09-09 2006-01-24 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
WO2006075124A1 (en) * 2005-01-14 2006-07-20 Camurus Ab Somatostatin analogue formulations
WO2006077362A1 (en) * 2005-01-21 2006-07-27 Camurus Ab Pharmaceutical lipid compositions
US7125954B2 (en) 2005-01-27 2006-10-24 General Electric Company Method for producing polyether polymers
WO2007060174A1 (en) * 2005-11-23 2007-05-31 Nestec S.A. Oil-in-water emulsion for creating new product consistencies
WO2007147002A2 (en) * 2006-06-13 2007-12-21 Wisconsin Alumni Research Foundation Beta-peptide lyotropic liquid crystals and methods of manufacture and use thereof
EP1677730A4 (en) * 2003-10-08 2008-06-11 Lyotropic Therapeutics Inc Drug-delivery vehicles based on reversed liquid crystalline phase materials
CN101123949B (en) 2005-01-21 2012-06-13 卡穆鲁斯公司 Medicine lipid composition
US8541400B2 (en) * 2004-08-04 2013-09-24 Camurus Ab Compositions forming non-lamellar dispersions
US8546326B2 (en) 2005-06-06 2013-10-01 Camurus Ab Glp-1 analogue formulations
US8865695B2 (en) 2009-01-08 2014-10-21 Lipocine Inc. Steroidal compositions
US8871712B2 (en) 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
US8920782B2 (en) 2005-01-14 2014-12-30 Camurus Ab Topical bioadhesive formulations
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
US9668967B2 (en) 2008-08-22 2017-06-06 Camurus Ab Lipid formulations comprising a thiolated antioxidant
US9820934B2 (en) 2007-08-22 2017-11-21 Camurus Ab Acid containing lipid formulations
US9974861B2 (en) 2007-06-15 2018-05-22 Camurus Ab Peptide slow-release formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002076A1 (en) * 1982-11-26 1984-06-07 Fluidcarbon International Ab Method of preparing controlled-release preparations for biologically active materials and resulting compositions
EP0119867A1 (en) * 1983-03-21 1984-09-26 MANCHESTER R & D PARTNERSHIP Low birefringence encapsulated liquid crystal and optical shutter using same
EP0378403A2 (en) * 1989-01-12 1990-07-18 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5021195A (en) * 1988-02-10 1991-06-04 Lever Brothers Company Structured aqueous detergent compositions containing salting-out electrolytes and surfactants and methods of forming them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002076A1 (en) * 1982-11-26 1984-06-07 Fluidcarbon International Ab Method of preparing controlled-release preparations for biologically active materials and resulting compositions
EP0119867A1 (en) * 1983-03-21 1984-09-26 MANCHESTER R & D PARTNERSHIP Low birefringence encapsulated liquid crystal and optical shutter using same
US5021195A (en) * 1988-02-10 1991-06-04 Lever Brothers Company Structured aqueous detergent compositions containing salting-out electrolytes and surfactants and methods of forming them
EP0378403A2 (en) * 1989-01-12 1990-07-18 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Orbit Search Service, File WPAT, Accession Number 91-255500/35, DUMEX A/S et al.: "Compsn. for Controlled Release of Biologically Active Drug - Comprises Mono:Glyceride(s) and Plant Oil(s) contg. e.g. Metronidazole Derivs. Forming Inverted Hexagonal Phase on Water Contact"; & JP,A,03 135 925, 10 June 1991, (9135). *

Cited By (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444041A (en) * 1991-04-19 1995-08-22 Ibah, Inc. Convertible microemulsion formulations
US5633226A (en) * 1991-04-19 1997-05-27 Lds Technologies, Inc. Convertible microemulsion formulations
US5646109A (en) * 1991-04-19 1997-07-08 Lds Technologies, Inc. Convertible microemulsion formulations
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
US5707648A (en) * 1993-11-17 1998-01-13 Lds Technologies, Inc. Transparent liquid for encapsulated drug delivery
US5834013A (en) * 1994-06-08 1998-11-10 L'oreal Cosmetic or dermatological composition in the form of an aqueous and stable dispersion of cubic gel particles based on phytanetriol and containing a surface-active agent which has a fatty chain, as dispersing and stabilizing agent
EP0686386A1 (en) 1994-06-08 1995-12-13 L'oreal, S.A. Cosmetic and dermatologic composition comprising a stable aqueous dispersion of phytantriol-based gel particles containing a long-chain surfactant as dispersant and stabilizer
FR2720937A1 (en) * 1994-06-08 1995-12-15 Oreal An aqueous and stable cosmetic or dermatological composition in the form of phytantriol-based cubic gel particles containing a fatty-chain surfactant as a dispersing and stabilizing agent.
US6071524A (en) * 1994-11-10 2000-06-06 L'oreal Oily phase in aqueous phase dispersion stabilized by cubic gel particles and method of making
AU724655B2 (en) * 1996-06-10 2000-09-28 Eurocine Ab Immunstimulating lipid formulation
US7128909B2 (en) 1996-06-10 2006-10-31 Eurocine Ab Immunstimulating lipid formulation
WO1997047320A1 (en) * 1996-06-10 1997-12-18 Pharmatrix Ab Immunstimulating lipid formulation
WO1997047250A1 (en) * 1996-06-13 1997-12-18 Mehl Thomas L Sr Liquid crystals in dermatological treatments using light energy
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6482517B1 (en) 1997-09-09 2002-11-19 Select Release, L.C. Coated particles, methods of making and using
EP0942780A1 (en) * 1997-09-09 1999-09-22 Select Release, L.C. Coated particles, methods of making and using
US7105229B2 (en) 1997-09-09 2006-09-12 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
EP0942780A4 (en) * 1997-09-09 2001-01-10 Select Release L C Coated particles, methods of making and using
US6989195B2 (en) * 1997-09-09 2006-01-24 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
WO1999047004A1 (en) * 1998-03-13 1999-09-23 Societe Des Produits Nestle S.A. Food composition containing a monoglyceride mesomorphic phase
US6569478B1 (en) 1998-03-13 2003-05-27 Nestec S.A. Food composition containing a monoglyceride memomorphic phase
EP0948902A1 (en) * 1998-03-13 1999-10-13 Societe Des Produits Nestle S.A. Food composition comprising a mesomorphic phase of monoglyceride
US6936260B1 (en) 1999-02-12 2005-08-30 Eurocine Ab Vaccine composition
WO2000047225A2 (en) * 1999-02-12 2000-08-17 Eurocine Ab Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant
WO2000047225A3 (en) * 1999-02-12 2000-12-14 Pharmatrix Ab Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
EP1331913A2 (en) 2000-06-29 2003-08-06 THE PROCTER & GAMBLE COMPANY Cubic liquid crystalline compositions and methods for their preparation
DE10057770A1 (en) * 2000-11-22 2002-05-23 Beiersdorf Ag Cosmetic or dermatological composition comprises dispersed liquid crystals forming a cubic phase
WO2004108884A3 (en) * 2003-06-10 2005-02-17 Anna Imberg Composite materials and particles
WO2004108884A2 (en) * 2003-06-10 2004-12-16 Anna Imberg Composite materials and particles
EP1677730A4 (en) * 2003-10-08 2008-06-11 Lyotropic Therapeutics Inc Drug-delivery vehicles based on reversed liquid crystalline phase materials
EP2264126A3 (en) * 2003-10-08 2012-11-28 Lyotropic Therapeutics, Inc. Drug-delivery vehicles based on reversed liquid crystalline phase materials
EP1529519A3 (en) * 2003-11-07 2006-02-01 L'oreal Cosmetic use of cubic gel particles as agents against adhesion of microorganisms to the skin and/or mucosa
FR2861988A1 (en) * 2003-11-07 2005-05-13 Oreal Cosmetic use of cubic gel particles as agent preventing or reducing the adhesion of microorganisms on the surface of the skin and / or mucous membranes
EP1529519A2 (en) * 2003-11-07 2005-05-11 L'oreal Cosmetic use of cubic gel particles as agents against adhesion of microorganisms to the skin and/or mucosa
US8541400B2 (en) * 2004-08-04 2013-09-24 Camurus Ab Compositions forming non-lamellar dispersions
US9757461B2 (en) 2005-01-14 2017-09-12 Camurus Ab GnRH analogue formulations
US8871712B2 (en) 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
US9968680B2 (en) 2005-01-14 2018-05-15 Camurus Ab Topical bioadhesive formulations
WO2006075124A1 (en) * 2005-01-14 2006-07-20 Camurus Ab Somatostatin analogue formulations
US8920782B2 (en) 2005-01-14 2014-12-30 Camurus Ab Topical bioadhesive formulations
CN101123949B (en) 2005-01-21 2012-06-13 卡穆鲁斯公司 Medicine lipid composition
US9526788B2 (en) 2005-01-21 2016-12-27 Camurus Ab Pharmaceutical lipid compositions
US9060935B2 (en) 2005-01-21 2015-06-23 Camurus Ab Pharmaceutical lipid compositions
WO2006077362A1 (en) * 2005-01-21 2006-07-27 Camurus Ab Pharmaceutical lipid compositions
US7125954B2 (en) 2005-01-27 2006-10-24 General Electric Company Method for producing polyether polymers
US8546326B2 (en) 2005-06-06 2013-10-01 Camurus Ab Glp-1 analogue formulations
WO2007060174A1 (en) * 2005-11-23 2007-05-31 Nestec S.A. Oil-in-water emulsion for creating new product consistencies
WO2007147002A3 (en) * 2006-06-13 2008-02-07 Wisconsin Alumni Res Found Beta-peptide lyotropic liquid crystals and methods of manufacture and use thereof
US8021570B2 (en) 2006-06-13 2011-09-20 Wisconsin Alumni Research Foundation β-peptide lyotropic liquid crystals and methods of manufacture and use thereof
WO2007147002A2 (en) * 2006-06-13 2007-12-21 Wisconsin Alumni Research Foundation Beta-peptide lyotropic liquid crystals and methods of manufacture and use thereof
US9974861B2 (en) 2007-06-15 2018-05-22 Camurus Ab Peptide slow-release formulations
US9820934B2 (en) 2007-08-22 2017-11-21 Camurus Ab Acid containing lipid formulations
US9668967B2 (en) 2008-08-22 2017-06-06 Camurus Ab Lipid formulations comprising a thiolated antioxidant
US8865695B2 (en) 2009-01-08 2014-10-21 Lipocine Inc. Steroidal compositions
US9949985B2 (en) 2010-11-30 2018-04-24 Lipocine Inc. High-strength testosterone undecanoate compositions
US9480690B2 (en) 2010-11-30 2016-11-01 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9757390B2 (en) 2010-11-30 2017-09-12 Lipocine Inc. High-strength testosterone undecanoate compositions
US9205057B2 (en) 2010-11-30 2015-12-08 Lipocine Inc. High-strength testosterone undecanoate compositions
US9943527B2 (en) 2010-11-30 2018-04-17 Lipocine Inc. High-strength testosterone undecanoate compositions
US10226473B2 (en) 2010-11-30 2019-03-12 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US9757389B2 (en) 2014-08-28 2017-09-12 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters

Also Published As

Publication number Publication date
NO941191D0 (en) 1994-03-30
NO941191L (en) 1994-06-01

Similar Documents

Publication Publication Date Title
Zhigaltsev et al. Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing
Esposito et al. Lipid-based supramolecular systems for topical application: a preformulatory study
CA1337397C (en) Emulsified composition
EP0524968B1 (en) Heterovesicular liposomes
US4917951A (en) Lipid vesicles formed of surfactants and steroids
KR100588241B1 (en) Peptide-Lipid Complex Formation by co-lyophilization
US6245349B1 (en) Drug delivery compositions suitable for intravenous injection
Eeman et al. From biological membranes to biomimetic model membranes
Lawrence et al. Microemulsion-based media as novel drug delivery systems
US5716637A (en) Solid fat nanoemulsions as vaccine delivery vehicles
AU2001281786B2 (en) Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
US6143321A (en) Liposomes containing active agents
JP2756526B2 (en) Stabilization and liposomes suspensions liposome suspension
Lawrence et al. Microemulsion-based media as novel drug delivery systems
AU615453B2 (en) Method of preparing controlled-release preparations for biologically active materials and resulting compositions
Mozafari Nanoliposomes: preparation and analysis
Lovelyn et al. Current state of nanoemulsions in drug delivery
Salentinig et al. Self-assembled structures and p K a value of oleic acid in systems of biological relevance
KR900007185B1 (en) Liposome composition
KR100482390B1 (en) Micellar Nanoparticles
Laouini et al. Preparation, characterization and applications of liposomes: state of the art
Mahale et al. Niosomes: novel sustained release nonionic stable vesicular systems—an overview
Dong et al. Bulk and dispersed aqueous phase behavior of phytantriol: effect of vitamin E acetate and F127 polymer on liquid crystal nanostructure
JP5222739B2 (en) Stable Nano encapsulation system for the administration of active molecules
Kozubek½ et al. Liposomal drug delivery, a novel approach: PLARosomes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1993906328

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2120359

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2120359

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 941538

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 08211293

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1993906328

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993906328

Country of ref document: EP